

Calculating the burden of disease of avian-origin H7N9 infections in China

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-004189
Article Type:	Research
Date Submitted by the Author:	09-Oct-2013
Complete List of Authors:	Qi, Xiaopeng; Chinese Center for Disease Control and Prevention, National center for public health surveillance and information services Jiang, Dong; Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Wang, Hongliang; The 2nd Affiliated Hospital of Harbin Medical University, ICU Zhuang, Dafang; Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Ma, Jiaqi; Chinese Academy of Sciences, Ma, Jiaqi; Chinese Academy of Sciences, Cutrol and Prevention, National Center for Public Health Surveillance and Information Services Fu, Jingying; University of Chinese Academy of Sciences, Qu, Jingdong; The 2nd Affiliated Hospital of Harbin Medical University, Su, Yan; School of Public Health, Harbin Medical University, Yu, Shicheng; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Meng, Yujie; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Huang, Yaohuan; Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Xia, Lanfang; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services U, Yingying; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Wang, Yong; Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Wang, Guohua; School of Public Health, Harbin Medical University, Xu, Ke; College of Geoscience and Surveying Engineering, China University, Xu, Ke; College of Geoscience and Surveying Engineering, China University of Mining & Technology(Beijing), Zhang, Qun; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Wan, Ming; Chinese Center for Disease Control and Prevention, National Center for Public Health
Primary Subject Heading :	Health economics
Secondary Subject Heading:	Public health

Keywords:	Burden of diseases, H7N9, HEALTH ECONOMICS
Note: The following files were su PDF. You must view these files	bmitted by the author for peer review, but cannot be converted t (e.g. movies) online.
Figure_BMJ.zip	
	SCHOLARONE Manuscripts
	Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Burden of diseases in the 21st century:

A case of emerging H7N9 influenza virus infection in China

Xiaopeng Qi^{1*}, Dong Jiang^{2*}, Hongliang Wang^{3*}, Dafang Zhuang^{2*}, Jiaqi Ma^{1*}, Jingying Fu^{2,4}, Jingdong Qu³, Yan Sun⁵, Shicheng Yu¹, Yujie Meng¹, Yaohuan Huang², Lanfang Xia¹, Yingying Li¹, Yong Wang², Guohua Wang⁵, Ke Xu⁶, Qun Zhang¹, Ming Wan¹, Xuemei Su¹, Gang Fu¹, George F Gao⁷

*These authors contributed equally to this work

- National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing, China,
- 2 State Key Laboratory of Resources and Environmental Information System, Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing, China,
- 3 The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China,
- 4 University of Chinese Academy of Sciences, Beijing, China,
- 5 School of Public Health, Harbin Medical University, Harbin, China,
- 6 College of Geoscience and Surveying Engineering, China University of Mining & Technology(Beijing), Beijing, China,
- 7 Office of the Director, Chinese Center for Disease Control and Prevention, Beijing, China

Correspondence to:

Dr XP Qi, National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing 102206, China

qixp@chinacdc.cn

and

Prof G F Gao, Office of the Director, Chinese Center for Disease Control and Prevention, Beijing 102206, China

gaofu@chinacdc.cn

Abstract

Objective In China, 134 cases of avian-origin H7N9 infections have been confirmed since February 2013. We aimed to calculate the overall burden of H7N9 cases in China as of May 31, 2013 to give an example of comprehensive burden of disease in the 21st century of an acute animal-borne emerging infectious disease.

Design We present an accurate and operable method for estimating the burden of H7N9 cases in China. The main drivers of economic loss were identified. Costs were broken down into direct (outpatient and inpatient examination and treatment) and indirect costs (cost of DALY and losses in the poultry industry), which were estimated based on field surveys and statistical data.

Setting Models were applied to estimate overall burden of H7N9 cases in China.

Participants 131 Laboratory confirmed H7N9 cases (excluding one Taiwan case) by May 31, 2013.

Outcome measure Burden of H7N9 cases including direct and indirect losses.

Results The total direct medial cost was 16,422,535 CNY. The mean cost for each patient was 10,117 CNY for mild patient, 139,323 CNY for severe cases without death, and 205,976 CNY for severe cases with death. The DALYs were 677.848 and the total cost of DALYs was 17,356,561 CNY. Poultry-industry losses were estimated on three levels: 27 prefectures with cases, 10 affected provinces and eight non-affected adjacent provinces, including the costs of closing the live-poultry market and slaughter. The poultry industry losses amount to 7.75 billion CNY in 10 affected provinces and 3.68 billion CNY in eight non-affected adjacent provinces.

Conclusions The number of H7N9 incidence cases decreased accompanied by closing the live-poultry markets and slaughtering the poultry. However, the medical cost per case and DALY per case were extremely high (esp. addressing the use of modern medical device). Cost-effectiveness assessment for the intervention needs to be done in future study.

Article summary

Strengths and limitations of this study

- This study is the first (to our knowledge) in which comprehensive methods were applied to identified the main drivers of economic losses and estimate the burden of disease due to H7N9 infection including direct cost (medical cost) and indirect cost (death, disability and poultry-industry losses);
- This study has some limitations. Estimation of the medical cost was based on the model and second hand data, not on the H7N9 patients' original costs. The burden of H7N9 might be underestimated since the ongoing costs of existing cases and new cases after May 2013, underreported cases and other losses involved in the livestock-production chain were not included in our study.

Introduction

A novel avian-origin influenza A (H7N9) virus has caused severe disease in humans in China since February 2013. The high number of new cases within a short period and the high case fatality rate have caused public panic and attracted global attention. It was also reported from media that some patients' families undertook large medical costs. According to the literature, exposure to live poultry could be an important risk factor for human infection with H7N9. ¹⁻³ As a result, closing-down the live-poultry markets and slaughtering the poultry were the main intervention measures in affected areas in China. These interventions played an important role in disease prevention, but on the other hand, also caused serious losses to the poultry industry.

The introduction of the novel virus led to numerous investigations on the origin of the virus, its genes, clinical symptoms, laboratory test, treatment and transmission ⁴⁻⁶; however, the burden of human infection with H7N9 has not yet been measured. It is important to estimate the overall burden of disease (BOD) due to H7N9 in China because this virus is new in humans and could cause a global pandemic in the future. The Global Burden of Disease (GBD) 2010 study presents a comprehensive methodological framework for death and disability loss estimation and has had a pronounced impact on the estimation of BOD ⁷⁸. In this study, we identified the main drivers of economic losses and summarized the direct and indirect costs of human H7N9 infection. We aimed to present an accurate and operable approach for estimating the overall burden of emerging infectious diseases and to provide evidence on the cost effectiveness of H7N9 prevention and control. We also aim to set up a BOD estimation example for any animal-borne infectious diseases, esp. with the introduction of modern medical device.

Methods

Case category definition

The confirmed human infections of H7N9 were divided into mild and severe cases based on the "Diagnostic and treatment protocol for human infections with avian influenza A (H7N9) (2nd edition, 2013)".⁹ Mild cases presented with influenza-like illness (ILI), while severe cases developed quickly and presented with severe pneumonia, usually accompanied by severe complications and organ failure. Severe illness was divided into 'severe without death' and 'severe with death'. The 11 H7N9 cases of unknown status were classified as 'unknown without death'.

Data source

Data on the 131 confirmed cases of H7N9 by the end of May 31, 2013 came from China's information system for disease control and prevention and included basic information on the onset of illness, epidemiology and emergency event reporting. Disability-adjusted life years (DALYs) were calculated based on two other published sources. The World Health Organization (WHO) provided a table of life expectancy by age for China in 2011,¹⁰ while the Institute for Health Metrics and Evaluation (IHME) published the Global Burden of Disease (GBD) 2010, including the GBD 2010 Disability Weights .¹¹ Disability weights of general infectious disease (acute episode for mild, moderate and severe) were adopted from IHME based on the clinician's

suggestion though the symptoms of H7N9 cases were more severe than the general infectious disease cases. The 2012 per-capita gross domestic product (GDP), which was used to calculate the cost of lost lives or the cost of disability, was obtained from the National Bureau of Statistics of China.

Poultry production and trade data from27 prefectures with confirmed H7N9 cases, including live-poultry sales, dates of live-market closings and market-stall volumes, were collected from field surveys, local livestock-breeding year books ¹² and the 'Chinese Commodities Trading-Market Statistics Yearbook 2012'.¹³ Data were gathered from the ten affected provinces and eight unaffected adjacent provinces. These data were used to estimate poultry-industry losses.

Analysis framework of burden of confirmed H7N9 cases

We constructed a framework for BOD analysis (Figure 1). We described the confirmed H7N9 cases category as mild, severe without death, severe with death and unknown without death and examined the spatiotemporal and population characteristics of these cases. Based on the case category and characteristics of case spatiotemporal distribution, costs were broken down into direct medical costs (outpatient and inpatient examination and treatment) and indirect costs (death, disability and poultry-industry losses). To calculate the DALYs attributable to H7N9, the H7N9-specific years of life lost due to premature mortality (YLLs) and years lived with disability (YLDs) were computed and then summed. An intensive analysis of poultry-industry losses would be complex and would require time-consuming field surveys. Meanwhile, indirect effects may lag behind. In this paper, we considered only the poultry industry losses caused from the closing of live-poultry markets and the large-scales laughter of poultry.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Statistical analysis

Descriptive statistics were used to summarize the epidemiologic characteristics of the cases. The distribution of confirmed H7N9 cases by week was also extracted by creating two standard deviational ellipses (covering 95% of the points while calculating the standard deviation of the x-coordinates and y-coordinates from the mean center to define the axes of the ellipse) to summarize the spatial spread of confirmed H7N9 cases (central tendency, dispersion and directional trends). If the number of cases in one week was less than three, those cases were not included in the calculation.

The methods for estimating direct medical costs are traditionally classified into two broad approaches: bottom-up (micro-costing) and top-down (macro-costing).^{14 15} In general, the bottom-up approach usually results in a higher but more accurate estimate.¹⁶ In our study, we used the bottom-up approach to estimate the direct medical costs. Four cost drivers were extracted: cost of outpatient and inpatient examinations in ward, cost of examination in intensive-care units (ICUs), cost of treatment and other costs (including medical consumables, charge for sickbed, general care services, checkup fee, etc). A cost formula was constructed for each driver, as depicted in Table 1. The cost per patient was estimated by experienced hospital financial officers and hospital doctors. The mean number of days (ICU stay, hospital stay and days of treatments) was estimated from the epidemiologic data. The number of patients for each driver was derived

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

from a previous publication.⁶ Professionals' experiences were also considered for some items that were not included in our surveillance system. The costs for the category 'unknown without death' were assumed to be moderate and were set as the average of the costs of mild cases and severe cases without death.

The YLLs for confirmed H7N9 cases in China were calculated from the sum of the number of fatal cases (n) in 5-year age groups (i) multiplied by the remaining expected life span (e) based on the age of death for that age group:¹⁷ (formula 1)

$$YLLs = \Sigma \mathbf{n}_i \times \mathbf{e}_i \tag{1}$$

To estimate the burden of H7N9 in YLLs, the Chinese life-expectancy table from WHO 2011 was used.

The YLDs were calculated by multiplying the duration of illness (t) by the disability weights (w) accumulated over all H7N9 cases (d) for each health outcome (j): (formula 2)

$$YLDs = \sum d_j * t_j * W_j$$
⁽²⁾

As H7N9 is a relatively new infectious disease and the health state of patients after discharge is unknown, we calculated the YLDs only as general acute episodes of infectious disease during the hospital stay. Disability weights were assigned as infectious disease (mild, moderate and severe acute episodes).¹¹

The DALYs are calculated by adding YLLs to morbidity and disability, expressed in YLD (formula 3).

$$DALYs = YLLs + YLDs$$
(3)

An estimation of the cost of one DALY was based on the traditional human-capital approach for per-capita GDP (formula 4). Considering the different production capabilities at different ages, the weights of production capability were calculated. The following weights were used according to the literature: 0.15 at age 0-14, 0.75 at age 15-44, 0.8 at age 45-59 and 0.1 at age 60+.¹⁸

As mentioned above, direct poultry-industry losses (PIL) can be calculated using formula 5:

$$PIL = L_1 + L_2 \tag{5}$$

where L_1 is the loss from poultry slaughter and L_2 is the loss from the closing of live-poultry markets, which includes the lost sales of live poultry (L_{21}) and fees for market-stall leases (L_{22}). A cost formula was constructed for the estimation of poultry industry loses (Table 2).

Results

Epidemiologic characteristics for different case categories

A total of 131 confirmed H7N9 cases in ten provinces in China were mapped as individual points based on detailed addresses (Figure 2). Most (81%) of the patients were located in the Jiangsu, Shanghai and Zhejiang provinces. Most of the cases (73% or above) in ten provinces were severe. There were 25 mild cases, 56 severe cases without death, 39 severe cases with death and 11 unknown cases without death in China through May 31, 2013.

Figure S1 is the presentation of the rate, direction and scope of the H7N9 spread. Each ellipse covers 95% of the incident cases for one week. The location of the first week of H7N9 onset was in Shanghai. Over the next few weeks, the epidemic extended to the Jiangsu and Zhejiang provinces and continued to grow. The virus quickly spread from the northwest to the north and south regions.

The onset of most H7N9 cases was relatively clustered. Within the total event timeframe (2/19–5/21), 74% of the cases were infected between 3/28-4/17 (Figure S2). Severe cases with death were found in the initial and intermediate stages. The median age of patients with confirmed H7N9 virus infection was 61 years (range, 3 to 91). Severe symptoms tended to occur in older people. The median age of patients who were severely ill without death was 60 years, while the median age of patients who were severely ill with death was 69 years. The number of mild cases distributed on all age groups under 80 years (Figure S3).

Direct medical costs of confirmed H7N9 cases

After the confirmed H7N9 cases occurred in China, the patients' clinical manifestations, examinations and treatments were published,⁶ which allowed us to estimate the direct medical costs using a cost model. We separated the examination data into examinations conducted in ward and examinations in ICU, as the latter were more frequent. The main treatments for confirmed H7N9 cases were selected. In our cost formula, three main factors were considered: cost per day, number of days and number of patients. For the cost-per-day estimation, we selected a Grade-III Class-A hospital (general large-scale hospital in China). Costs per day were obtained from the hospital financial officers and hospital doctors based on the average costs of patients with same treatments from Jan.1, 2013 to May 31, 2013 in this hospital (Table S1). Differences in costs among the regions in China were approximately 10%.

The mean number of days and number of cases were estimated from a subset of the investigated cases (Table 3). Data regarding hospital stay were available for 11 of the 25 mild cases, 19 of the 56 severe cases without death and 19 of the 39 severe cases with death. The mean length of stay was 9 days for mild cases, 18 days for severe cases without death and 20 days for severe cases with death. Data on the duration of ICU stay were available for ten of the 56 severe cases without death and 11 of the 39 severe cases with death. Severe cases without death stayed in

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

the ICU for a mean of 12 days, while severe cases with death stayed for a mean of 16 days. We assumed that the mean hospital stay of severe cases with complications was equal to the length of the ICU stay, although complications might occur incrementally. The mean durations of different treatments lasting were also estimated based on a subset of investigated patients, except for glucocorticoids and intravenous immune globulin, for which estimates were obtained from professionals' experiences. Treatment for complications required drugs and examinations in addition to the treatment listed above. Treatment was described for 111 confirmed H7N9 cases, along with the proportion of patients who received each treatment.⁶ We assumed that the proportions were generalizable to all cases because it covered 85% of cases.

Table S2 is the summary of all of the direct medical costs. The total cost for all 131 patients with confirmed H7N9 virus infection was 16,422,535 CNY (2,627,606 USD). The mean cost for each patient was 10,117 CNY (1,619 USD) for mild patient, 139,323 CNY (22,292USD) for severe cases without death, and 205,976 CNY (32,956USD) for severe cases with death. The mean cost per day was 1,124 CNY (180 USD) for mild cases, 8,293 CNY (1,327 USD) for severe cases without death and 8,978 CNY (1,437 USD) for severe cases with death. As the severity of the illness increased, the costs increased correspondingly.

Cost of DALYs on H7N9

A total of 39 deaths from confirmed H7N9, including 30 males and 9 females, were reported from the National Health and Family Planning Commission of China by 31 May 2013. For more details on the number of cases in each age group, see Table S3.The total YLLs were 676.89. There were 131 H7N9 cases, including 25 mild cases, 95 severe cases and 11 of unknown category (assumed to be moderate). YLD calculations were based on the case category. The total YLLs were 1.064 (Table S4). The DALYs combine the time lived with disability and the time lost due to premature mortality; thus, the DALYs were 677.848 for all confirmed H7N9 patients. We adopted 2012 per-capita GDP of the ten provinces and estimated the cases adjusted per-capita GDP (65,655 CNY). By calculating the weight of production capability for each age group, we got the average weight of production capability to be 0.39 for all confirmed H7N9 cases. The total cost of DALYs was 17,356,561 CNY (2,777,050 USD) according to the formula 4.

Poultry-industry losses

Poultry-industry losses were estimated for three categories (Figure 3): 1)27 prefectures with confirmed H7N9 cases (region 1, in brown in Figure 3), 2)10 affected provinces (region 2, in yellow in Figure 3) and 3) eight non-affected adjacent provinces (region 3, shadowed in Figure 3).

In region1, three types of losses were calculated: losses from poultry slaughter, lost sales of live poultry and fees for market-stall leases. In the ten affected provinces (region 2), in addition to the losses in region1, the losses mainly arose from the closing-down of live-poultry markets in each province. These two losses were then summed to estimate poultry-industry losses caused by H7N9 outbreaks. Most of the main live-poultry markets in the affected provinces (presented in Figure 3) were obtained from Google Earth; the retail locations were excluded.

BMJ Open

Poultry-industry losses in eight non-affected adjacent provinces (region 3) were also calculated as potential economic losses. The direct poultry-industry losses of 27 prefectures for the H7N9 cases are described in detail in Table 4.

The cost of closing-down live-poultry markets includes the lost sales of live poultry and fees for market-stall leases. The cost of lost sales of live poultry was calculated according to the daily live-poultry sales, the cost per animal (assumed to be 10 CNY in this paper) and the number of days the market was closed. The cost of market-stall leases was calculated based on the average lease per stall per day in the corresponding city, the number of stalls and the number of days the market was closed in each city. The cost of poultry slaughter was obtained from the number of poultry slaughtered and the cost per animal. The number of days the market was closed was counted through May 31 because there have been only one confirmed H7N9 cases since then. The total poultry-industry losses in the ten affected provinces, including 27 prefectures with H7N9 cases, are listed in Table 5. The poultry-industry losses of each province are presented in Figure S4.

In general, China's poultry industry suffered direct losses amounting to 7.75 billion CNY from when the first case of H7N9 was confirmed through May 31, 2013. Losses from the live-poultry trade account for 98% of the total losses. Although it had only a fewH7N9 cases, Shandong Province ranked first in losses among all ten provinces at 1.81 billion CNY; Jiangsu, Henan and Anhui ranked next, with 1.28 billion CNY, 1.15 billion CNY and 1.14 billion CNY, respectively. These provinces have large poultry markets. Zhejiang Province had the highest number of confirmed cases; however, the losses in that region were not very high, as the sales of live poultry were lower. Strict prevention and control measures, such as daily cleaning of the market, weekly disinfection of the market and monthly closings of the live market, were conducted in Guangdong Province, which reported no H7N9 cases till 31 May 2013 during the emergency response. Meanwhile, these prevention and control measures affected the poultry industry. For this reason, the poultry-industry losses in Guangdong Province are also given in Table 5.

Due to timely control measures, the H7N9-affected regions were limited to the 27 prefectures in ten provinces in China. In this study, the potential economic risks were also calculated for the eight non-affected adjacent provinces (region 3, shadowed in Figure 3). Table S5 shows that the potential losses to the poultry industry in those regions amount to 3.6 billion CNY.

Discussion

This study was based on illness severity and spatiotemporal aspects of the recent avian-origin influenza A (H7N9) infections. Our results indicate that there were clusters of patients infected with H7N9 in China. Of the 131 patients, 81% resided in the Jiangsu, Shanghai and Zhejiang provinces, and 74% were infected during the period of 3/28-4/17. Patients over 50 years of age accounted for 72% of the total, and 95 patients (73.1%) were diagnosed as severe cases. The fatality rate of confirmed H7N9 cases in China was 26.9%.

 We assumed that cases of the same severity resulted in similar medical costs. Therefore, mild cases, severe cases without death, severe cases with death and unknown cases without death were estimated separately by calculating the mean number of days, number of cases and cost per day. The mean cost per patient was 8,880 CNY (1,421 USD) for mild cases, 144,788 CNY (23,166 USD) for severe cases without death and184, 211 CNY (29,474 USD) for severe cases with death. The total direct medical cost for all patients was 15,963,935 CNY (2,554,230 USD). The DALYs, which were determined from the YLLs and YLDs, were 677.848 years for all confirmed H7N9 cases. The total cost of the DALYs was 17,356,561 CNY (2,777,050 USD) according to the average GDP per capita and average weight of production capability.

Compared to the poultry-industry losses, the direct medical losses and DALY losses were relatively small. To a large extent, the small number of patients in the H7N9 outbreak in China was due to quick and effective interventions, which prevented a pandemic. The estimation of direct medical cost and DALY cost, especially the mean cost per patient and mean cost per day for different case categories, can be used to guide those counties in which H7N9 cases did not occur in the prevention and control of H7N9. DALY per H7N9 case (5176 DALYs per 1000 cases) was much higher than the other respiratory infectious diseases according to the 2010 GBD study.¹⁹ A comparison to outbreaks of other infectious diseases (with similar clinical symptom) was also considered in this report. The health care cost per SARS patient in Beijing was 17,150 CNY (1,886USD) while the average medical cost per H7N9 patient was 99,691 CNY(15,951 USD) because of the higher fatality rate of H7N9 patients and more expensive modern medical device had been used.²⁰

As of the end of May, China's poultry industry suffered direct losses amounting to 7.75 billion CNY, including the cost of closing live-poultry markets and slaughtering poultry in the ten affected provinces. Poultry-industry losses were estimated at three levels: 27 prefectures with confirmed H7N9 cases, 10 affected provinces and eight non-affected adjacent provinces. The outbreak of H7N9 may reduce the demand for poultry products in other regions of China, due to public perceptions. These effects were not considered in this paper. The cost of closing-down the live-poultry markets and the cost of poultry slaughter were calculated as direct poultry-industry losses. We assumed that the cost per animal is 10 CNY and the date for the end of closing the live-poultry markets was May 31, 2013 because there has been only one confirmed H7N9 case since then. Losses from the live-poultry industry account for 98% of the total losses, with the lost sales of live poultry constituting the majority of that amount. Strict prevention and control measures have been enacted in Guangdong Province, which had few reported cases of H7N9. This finding will be significant for similar cases in the future. Due to timely control measures, the effects of the outbreak were limited to 27 prefectures in ten provinces in China.

Our study had several limitations. First, there were 11 confirmed H7N9 cases without death whose case categories were unknown. The cost estimation for these unknown patients was replaced by the average cost of mild and severe cases without death. Second, in the cost model, some of the data (e.g., mean number of days of ECMO for severe without death cases) were obtained from a small proportion of investigated cases, which could result in an estimation bias. Third, the direct medical cost did not include opportunity cost,²¹ the cost that is incurred because a limited resource is used to treat a preventable disease and cannot therefore be used to treat another

BMJ Open

disease.²² The medical practitioners' salary, research funding and loss of working time for family numbers of patients on H7N9 were excluded in our study. Fourth, estimations of the direct medical cost per day might show large differences for specific cases because the drug cost could grow considerably if imported and nutritional drugs were used. We considered only the average severity for patients in ward and in ICU. Fifth, 17 patients were still in hospital by May 28, 2013 according to the literature.²³ The mean numbers of days in ward and in ICU of severe cases and fatality rate were thus underestimated. And some of the mild cases may not be reported which also resulted in the underestimation of the cost. Sixth, in this paper, we considered only direct losses from the closing-down of live-poultry markets and large-scale poultry slaughter, which could be estimated accurately and quickly. This estimation is useful for early control and decision-making; however, other losses involved in the livestock-production chain, such as increased breeding costs, poultry seeding, the prices of poultry meat and eggs and the decreasing production of poultry-feather industries, should be considered in further studies.²⁴

In conclusion, we presented a quick, operable and accurate framework for estimating the burden of human infections with H7N9. This framework could be used in the BOD analysis of future H7N9 or similar outbreaks. The results, including direct and indirect costs, provide fundamental information for researchers, the public and policy makers to support timely and effective interventions.

Contributors

All authors participated in the conception and design of the report. XQ and GFG designed and supervised the study, and applied the grants. XQ, DJ, HW, DZ, JM, JF, JQ, YS, GW, KX collected data. XQ, DJ, JF, SY, YM, YH, LX, YL, YW, XS and GF analyzed data. QZ, MW, LX and YL took literature search, XQ and DJ drafted the manuscript, and all authors contributed to review and revision and have seen and approved the final version.

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding This research was supported by the National Basic Research Program of China (973 Program) (2012CB955504). None of the study sponsors had a role in the study design, data collection, analysis and interpretation, report writing, or the decision to submit the report for publication.

Data sharing No additional data available.

Supplementary material

- Figure S1 The directional distribution of confirmed H7N9 cases by week
- Figure S2 Date of illness onset by case category
- Figure S3 Age distribution of each case category

- Figure S4 Poultry-industry losses of each province
- Table S1
 Estimation of costs per day for confirmed H7N9 cases
- Table S2Summary of direct medical costs
- Table S3 YLLs of confirmed H7N9 cases
- Table S4 YLDs of confirmed H7N9 cases
- Table S5 Potential poultry-industry losses of eight non-affected adjacent provinces
- (DOC)

Acknowledgements

We thank Zijian Feng and Qun Li (Public Health Emergency Center, Chinese Center for Disease Control and Prevention) for data sharing and valuable suggestions. We thank Maigeng Zhou (National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention) for help with statistical analysis.

<text>


BMJ Open


References


- 1. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. *The New England journal of medicine* 2013.
- Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. *Lancet* 2013;381:1916-25.
- 3. Bao CJ, Cui LB, Zhou MH, Hong L, Gao GF, Wang H.(2013) Live-animal markets and influenza A (H7N9) virus infection. *The New England journal of medicine* 2013; 368: 2337-39.
- Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. *Lancet* 2013;381:1926-32.
- 5. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. *The New England journal of medicine* 2013;368:1888-97.
- Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. *The New England journal of medicine* 2013;368:2277-85.
- 7. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. *Lancet* 2012;380:2063-6.
- Murray CJ, Frenk J, Piot P, Mundel T. GBD 2.0: a continuously updated global resource. *Lancet* 2013.
- Diagnostic and treatment protocol for human infections with avian influenza A (H7N9)(2n d edition, 2013), 2013. Available: <u>http://www.moh.gov.cn/mohgjhzs/s7952/201304/98ceede1da</u> <u>f74a45b1105f18c4e23ece.shtml</u> Accessed 10 June 10 2013.
- Life expectancy: Life tables China, 2011. Available: <u>http://apps.who.int/gho/data/view.main.6</u> 0340?lang=en Accessed 10 June 2013.
- 11. GBD 2010 Disability Weights 2010. Available: <u>http://ghdx.healthmetricsandevaluation.org/gl</u> <u>obal-burden-disease-study-2010-gbd-2010-data-downloads</u> Accessed 10 June 2013.
- 12. China Animal Industry Yearbook. Beijing: China Agricultural Press, 2012.
- Statistical Yearbook of China Commodity Exchange Market. Beijing: Foreign Economy Statistics Division, National Statistics Bureau; Market Operation and Consumer Promotion Divison of Ministry of Commerce; Information Department of Commerce Association of China, 2012.
- 14. Lipscomb J, Yabroff KR, Brown ML, Lawrence W, Barnett PG. Health care costing: data, methods, current applications. *Medical care* 2009;47:S1-6.
- 15. Allorto NL, Clarke DL, Thomson SR. A cost model case comparison of current versus modern management of burns at a regional hospital in South Africa. *Burns : journal of the International Society for Burn Injuries* 2011;37:1033-7.
- Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. *Health economics* 2009;18:377-88.
- 17. Polinder S, Haagsma JA, Stein C, Havelaar AH. Systematic review of general burden of disease studies using disability-adjusted life years. *Population health metrics* 2012;10:21.
- 18. Du L, Wang J, Luo B, Pan B, Chen J, Zhou R, et al. Research on disease burden of SARS patients in Guangzhou city. *Chinese Journal of Public Health* 2007;23:379-81.
- 19. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life

years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2197-223.

- Xiao F, Chen BW, Wu YF, Wang YX, Han DM. Analysis on the cost and its related factors of clinically confirmeds severe acute respiratory syndrome cases in Beijing. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi* 2004;25:312-6.
- 21. O'Shea C. Opportunity cost. Australian Family Physician 2011;40:261-61.
- 22. Kong V, Aldous C, Handley J, Clarke D. The cost effectiveness of early management of acute appendicitis underlies the importance of curative surgical services to a primary healthcare programme. *Annals of the Royal College of Surgeons of England* 2013;95:280-4.
- 23. Yu H, Cowling BJ, Feng L, Lau EHY, Liao Q, Tsang TK, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. *The Lancet* 2013.
- 24. FAO. Highly pathogenic avian influenza in Mexico (H7N3) a significant threat to poultr y production not to be underestimated. Empres Watch: EMPRES WATCH, 2012. Available: ot n. <u>orp/docrep/016/a...</u> http://www.fao.org/docrep/016/an395e/an395e.pdf Accessed 15 June 2013.











Figure 2. Spatial distribution of 131 confirmed H7N9 cases. (Figure 2 presented the spatial distribution of 131 confirmed H7N9 cases severity in China. Mild, severity without death, severity with death and unknown without death cases were differentiated by diverse colors. The points were mapped based on the coordinates of the addresses. Areas with high density of cases were magnified on the top right corner. The map was drawn with ArcGIS 10.0 software.)

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.






Figure 3. Three types of regions for poultry-industry losses estimation. (Figure 3 presented poultry-industry losses which were estimated for three categories including 27 prefectures, 10 affected provinces and eight non-affected adjacent provinces. Points represented most of the main live-poultry markets which were obtained from Google Earth excluding the retail locations. The map was drawn with ArcGIS 10.0 software.)

Table 1. Formula for calculating direct medical costs

Cost	Formula
Cost of examination for outpatient and	Contained the strength of the
inpatient in ward (laboratory and radiology)	Cost per patient * number of patients
Cost of examination in ICU	
(laboratory and radiology)	Cost per day * mean number of days of ICU stay * number of patients
Cost of treatment	
Antiviral	Cost per day * mean number of days * number of patients
Antibiotics	Cost per day * mean number of days * number of patients
Other drugs	Cost per day * mean number of days * number of patients
Glucocorticoids	Cost per day * mean number of days * number of patients
Intravenous immune globulin	Cost per day * mean number of days * number of patients
Oxygen therapy	Cost per day * mean number of days of hospital stay * number of patient
ICU care	Cost per day * mean number of days of ICU stay * number of patients
ICU monitor	Cost per day * mean number of days of ICU stay * number of patients
Mechanical ventilation	
Noninvasive	Cost per day * mean number of days * number of patients
Invasive	Cost per day * mean number of days * number of patients
Artificial-liver-support-system therapy	Cost per day * mean number of days * number of patients
Continuous renal-replacement therapy	Cost per day * mean number of days * number of patients
Extracorporeal membrane oxygenation (ECMO)	Cost per day * mean number of days * number of patients
Complications	
ARDS	Cost per day * mean number of days of ICU stay * number of patients
Shock	Cost per day * mean number of days of ICU stay * number of patients
Acute kidney injury	Cost per day * mean number of days of ICU stay * number of patients
Rhabdomyolysis	Cost per day * mean number of days of ICU stay * number of patients
Other costs [§]	Cost per day * mean number of days of hospital stay * number of patien

[§]Other costs include medical consumables, charge for sickbed, general care services, checkup fee, etc.

Table 2. Formula for calculating poultry-industry losses

Cost	Formula
Cost of poultry slaughter (L1)	Cost per animal* number of poultry killed
Cost of closing live-poultry markets (L2)	
Cost of live-poultry sales(L21)	Live-poultry sales per day * cost per animal * number of days
Cost of market-stall leases (L22)	Cost of lease per stall per day * number of stalls * number of days

Table 3. Driver measurement

	Mild		Severe without de	ath	Severe with death		Unknown v	vithout death	D (
Category	Mean number of days (no. of cases investigated/total cases)	Number of cases	Mean number of days (no. of cases investigated/total cases)	Number of cases	Mean number of days (no. of cases investigated/total cases)	Number of cases	Mean number of days [¶]	Number of cases	- Reference proportion of patients (%)*
Hospital stay	9(11/25)	25	18(19/56)	55	20(19/39)	38	14	11	98.2
ICU stay	0	0	12(10/56)	55	16(11/39)	38	6	7	76.6
Treatment									
Antiviral	7(3/25)	24	7(20/56)	54	11(11/39)	38	7	11	97.3
Antibiotics	8(4/25)	17	11(21/56)	40	14(16/39)	28	9	8	71.2
Other drugs	9(11/25)	25	12(10/56)	55	16(11/39)	38	11	11	98.2
Glucocorticoids	0	0	7 [§]	43	7 [§]	30	4	8	62.2
Intravenous immune globulin	0	0	5 [§]	37	5 [§]	26	3	7	53.2
Oxygen therapy	9(11/25)	25	18(19/56)	56	20(19/39)	39	9	11	100.0
Mechanical ventilation									
Noninvasive	0	0	9(7/56)	19	3(6/39)	13	5	4	27.9
Invasive	0	0	8(7/56)	41	10(15/39)	28	4	8	58.6
Artificial-liver-support-system	0	0	4 [§]	11	4 [§]	7	2	2	15.3
therapy Continuous renal-replacement therapy	0	0	7 [§]	18	7 [§]	13	4	4	26.1
Extracorporeal membrane oxygenation (ECMO)	0	0	6(1/56)	12	7(2/39)	9	3	2	18.0
Complications									
ARDS	0	0	12(10/56)	50	16(11/39)	35	6	10	71.2
Shock	0	0	12(10/56)	18	16(11/39)	13	6	4	26.1
Acute kidney injury	0	0	12(10/56)	11	16(11/39)	8	6	2	16.2
Rhabdomyolysis	0	0	12(10/56)	7	16(11/39)	5	6	1	9.9
Other costs	9(11/25)	25	18(19/56)	55	20(19/39)	38	14	11	98.2
⁸ Based on the profe	e literature "Clinical Finding essionals' experiences of days for patient with unkn				mild and the severe cases with	out death			
				17					
	For	peer reviev	v only - http://bmjope	en.bmj.com/	site/about/guidelines.	khtml			

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Table 4. Poultry-industry losses of 27 prefectures with H7N9 case	Table 4. Poultry-	industry losses	of 27	prefectures	with H7N9	cases
---	-------------------	-----------------	-------	-------------	-----------	-------

Affected	Affected			Cost of closin	g live-poultry markets		Cost of
provinces (number of cases)	prefectures (number of cases)	Date	Live-poultry sales per day(10 ⁴)	Number of days	Cost of live-poultry sales(10 ⁴ CNY)	Market-stall leases(10 ⁴ CNY)	poultry slaughter (10 ⁴ CNY)
Beijing(2)	Beijing(2)	4.13	3.00	49	1470.00	6.93	0.50
Shanghai(32)	Shanghai(32)	4.05	11.94	57	6805.80	1703.16	20.54
Jiangsu(29)	Wuxi(4)	4.09	12.87	53	6821.10	527.40	0.40
	Yancheng(1)	4.15	8.18	47	3844.60	387.11	5.00
	Nanjing(12)	4.06	8.91	56	4989.60	567.84	8.00
	Zhenjiang(1)	4.09	8.55	53	4531.50	342.12	0.31
	Suzhou(7)	4.08	17.73	54	9574.20	265.03	0.01
	Yangzhou(1)	4.15	11.52	47	5414.40	180.17	0.20
	Xuzhou(1)	4.24	14.80	38	5624.00	380.30	0.10
	Changzhou(1)	4.11	8.94	51	4559.40	167.71	1.30
	Suqian(1)	4.02	10.14	60	6084.00	200.00	0.10
Zhejiang(45)	Huzhou(12)	4.11	6.14	51	3131.40	269.79	0.70
	Shaoxing(1)	4.22	5.31	40	2124.00	585.14	10.00
	Hangzhou(29)	4.15	12.48	47	5865.60	1200.20	24.66
	Jiaxing(2)	4.19	6.97	43	2997.10	1565.77	10.00
	Wenzhou(1)	4.21	7.02	41	2878.20	49.78	0.50
Auhui(4)	Bozhou(1)	4.09	2.89	53	1531.70	100.33	10.00
	Chuzhou(3)	3.30	6.19	63	3899.70	65.01	0.72
Fujian(5)	Longyan(1)	5.07	6.73	25	1682.50	77.40	0.82
	Fuzhou(4)	4.29	6.61	33	2181.30	287.76	100.00
Jiangxi(6)	Nanchang(5)	4.26	12.62	36	4543.20	45.72	0.10
	Yichun(1)	4.29	10.46	33	3451.80	14.09	0.08
Henan(4)	Zhoukou(1)	4.16	13.59	46	6251.40	18.28	1.60
	Kaifeng(1)	4.15	9.22	47	4333.40	14.81	1.80
	Zhengzhou(2)	4.15	9.01	47	4234.70	20.68	3.90
Hunan(2)	Shaoyang(2)	4.28	7.80	34	2652.00	70.10	100.00
Shandong(2)	Zaozhuang(2)	4.24	21.20	38	8056.00	52.36	0.66
Total cost (10 ⁴		128999.59					
Total cost (10 ⁴	USD)*	20639.93					

Note: 'Date' indicates the date on which the live-poultry markets were closed; 'days' is the number of days the live-poultry markets remained closed.

Table 5. Total amount of poultry-industry losses in the ten affected provinces (10⁴ CNY)

Affected provinces	Cost of live-poultry sales(10 ⁴ CNY)	Market-stall leases(10 ⁴ CNY)	Cost of poultry slaughter (10 ⁴ CNY)	Total cost (10 ⁴ CNY)	Total cost (10 ⁴ USD)
Beijing	14553.98	291.06	0.5	14845.54	2394.59
Shanghai	6805.8	1703.16	20.54	8529.5	1375.81
Jiangsu	124485.53	3181.5	25.62	127692.66	20596.83
Zhejiang	29982.14	2444.4	45.36	32471.9	5237.72
Anhui	113309.59	1113.01	11.52	114434.12	18458.22
Fujian	16723.29	509.04	100.82	17333.15	2795.84
Jiangxi	40832.88	255.36	0.18	41088.42	6627.56
Henan	114473.97	73.09	7.3	114554.36	18477.62
Hunan	32301.37	433.25	100	32834.62	5296.22
Shandong	180421.92	402.76	0.66	180825.34	29167.13
Guangdong	88827.4	1808.59	99.36	90735.35	14635.61
Total cost (10 ⁴ CNY)	762717.86	12215.21	411.87	775344.94	125063.14
Total cost (10 ⁴ USD)	123026.39	1970.31	66.43	125063.14	2394.59

Note: The date on which the live-poultry markets were closed varied among cities/counties. In table 5, the dates when the first case of H7N9 was confirmed were adopt for estimating the total amount of poultry-industry losses in each affected provinces.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Qi XP, Jiang D, Wang HL, et al. Burden of diseases in the 21st century: A case of emerging H7N9 influenza virus infection in China

Supplementary Appendix

Burden of diseases in the 21st century:

A case of emerging H7N9 influenza virus infection in China

Xiaopeng Qi^{1*}, Dong Jiang^{2*}, Hongliang Wang^{3*}, Dafang Zhuang^{2*}, Jiaqi Ma^{1*}, Jingying Fu^{2,4}, Jingdong Qu³, Yan Sun⁵, Shicheng Yu¹, Yujie Meng¹, Yaohuan Huang², Lanfang Xia¹, Yingying Li¹, Yong Wang², Guohua Wang⁵, Ke Xu⁶, Qun Zhang¹, Ming Wan¹, Xuemei Su¹, Gang Fu¹, George F Gao⁷

*These authors contributed equally to this work

- National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing, China,
- 2 State Key Laboratory of Resources and Environmental Information System, Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing, China,
- 3 The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China,
- 4 University of Chinese Academy of Sciences, Beijing, China,
- 5 School of Public Health, Harbin Medical University, Harbin, China,
- 6 College of Geoscience and Surveying Engineering, China University of Mining & Technology(Beijing), Beijing, China,
- 7 Office of the Director, Chinese Center for Disease Control and Prevention, Beijing, China

Correspondence to:

Dr XP Qi, National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing 102206, China

qixp@chinacdc.cn

and

Prof G F Gao, Office of the Director, Chinese Center for Disease Control and Prevention, Beijing 102206, China

gaofu@chinacdc.cn

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Contents

- Figure S1. The directional distribution of confirmed H7N9 cases by week
- Figure S2. Date of illness onset by case category
- Figure S3. Age distribution of each case category
- Figure S4. Poultry-industry losses of each province
- Table S1. Estimation of costs per day for confirmed H7N9 cases
- Table S2. Summary of direct medical costs
- Table S3. YLLs of confirmed H7N9 cases
- Table S4. YLDs of confirmed H7N9 cases
- Table S5. Potential poultry-industry losses of eight non-affected adjacent provinces




Figure S1. The directional distribution of confirmed H7N9 cases by week (The distribution of new confirmed H7N9 cases by week was extracted by creating two standard deviational ellipses covering 95% of the points in each ellipse to summarize the central tendency, dispersion and directional trends of confirmed H7N9 cases. The map was drawn with ArcGIS 10.0 software)

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.




Figure S2. Date of illness onset by case category (Based on the case categories, the graph presented the number of cases within each date of onset of H7N9 cases. It was drawn with Microsoft office Excel 2010 software.)




Figure S3. Age distribution of each case category (Based on the case categories, the graph presented the number of cases within each age group of H7N9 cases. It was drawn with Microsoft office Excel 2010 software.)




Figure S4. Poultry-industry losses of each province (The map presented the total losses of poultry industry in 10 affected provinces and the proportion of each kind of losses. It was drawn with ArcGIS 10.0 software.)

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Cost driver	Cost (CNY)	Note
Cost of examination of outpatients and inpatients in ward (laboratory and	2,500	Includes tests such as live function test, kidney function test, blood routine examination, routine
radiology) Cost of examination in ICU (laboratory and radiology)	1,700 per day	urinalysis, electrocardiogram, virus detection and isolation, chest radiology, computed tomography(CT), color Doppler ultrasound antibody testing for hepatitis, humar immunodeficiency virus and syphilis, throa swab, drug sensitive test, blood culture, ion test blood glucose, blood sedimentation, blood gas troponin, coagulation tests, procalcitonin (PCT) myocardial enzyme, D-dimer, C-reactive protein(CRP), B type natriuretic peptide.
Cost of treatment		
Antiviral	60 per day	Oseltamivir and peramivir, etc.
Antibiotics	350 per day	Fluoroquinolones, Piperacillin, Imipenem and Cephalosporin, etc.
	Mild: 270 per day	Reducing phlegm, relieving asthma, abating
Other drugs	Severe: 1,600 per day	fever, providing antioxidants and nutrition inducing sedating, etc.
Glucocorticoids	70 per day	
Intravenous immune globulin	2,500 per day	
Oxygen therapy	120 per day	
ICU care	1,100 per day	
ICU monitor	500 per day	
Mechanical ventilation		
Noninvasive	400 per day	
Invasive	1,000 per day	
Artificial-liver-support-system therapy	6000 per day	
Continuous renal-replacement therapy	9000 per day	
Extracorporeal membrane oxygenation (ECMO)	10,000 per day	
Complications		Excluding the treatments listed above
Adult respiratory distress syndro me (ARDS)	1,000 per day	Increases drug and special care services
Shock	800 per day	Increases drug, blood, fluid and hemodynamic monitoring
Acute kidney injury	300 per day	Increases drug
Rhabdomyolysis	600 per day	Increases drug use
Other costs	Mild: 200 per day	Medical consumables, charge for sickbed, genera
State (USIS	Severe: 800 per day	care services, checkup fee, etc.

Table S2. Summary of direct medical costs

	Mild	Severe	Severe with	Unknown	
Cost driver	(n=25)	without	death	without	Total cost
	(11 20)	death (n=56)	(n=39)	death (n=11)	
Cost of examination for outpatient and inpatient	62,500	137,500	95,000	27,500	322,500
in ward (laboratory and radiology)	02,500	137,500	95,000	27,500	522,500
Cost of examination in ICU	0	1,122,000	1,033,600	71,400	2,227,000
(laboratory and radiology)	0	1,122,000	1,055,000	/1,400	2,227,000
Cost of treatment					
Antiviral	10,080	22,680	25,080	4,620	62,460
Antibiotics	47,600	154,000	137,200	25,200	364,000
Other drugs	60,750	1,056,000	972,800	113,135	2,202,685
Glucocorticoids	0	21,070	14,700	2,240	38,010
Intravenous immune globulin	0	462,500	325,000	52,500	840,000
Oxygen therapy	27,000	144,000	93,600	11,880	276,480
ICU care	0	726,000	668,800	46,200	1,441,000
ICU monitor	0	330,000	304,000	21,000	655,000
Mechanical ventilation					
Noninvasive	0	68,400	15,600	8,000	92,000
Invasive	0	328,000	280,000	32,000	640,000
Artificial-liver-support-system therapy	0	264,000	168,000	24,000	456,000
Continuous renal-replacement therapy	0	1,134,000	819,000	144,000	2,097,00
Extracorporeal membrane oxygenation (ECMO)	0	720,000	630,000	60,000	1,410,00
Complications					
ARDS	0	600,000	560,000	60,000	1,220,00
Shock	0	172,800	166,400	19,200	358,400
Acute kidney injury	0	1,056,000	1,024,000	96,000	2,176,000
Rhabdomyolysis	0	50,400	48,000	3,600	102,000
Other costs	45,000	806,400	608,000	77,000	1,536,400
Total cost (CNY)	252,930	8,359,350	7,003,180	807,075	16,422,53
Total cost (USD)*	40,469	1,337,496	1,120,509	129,132	2,627,600
Mean cost for each patient (CNY)	10,117	139,323	205,976	73,370	107,197
Mean cost for each patient (USD)*	1,619	22,292	32,956	11,739	17,15
Mean cost per day for each patient (CNY)	1,124	8,293	8,978	5,765	6,040
Mean cost per day for each patient (USD)*	180	1,327	1,437	922	966

*Based on average exchange rate in May,2013: 1CNY=0.16USD

1	
2	
2 3 4 5 6 7 8	
4	
5	
6	
7	
8	
9	
1	0
1	1
1	2
1	2
1	1
1	- 5
1	5 6
1	7
1	1 0
1	0
1	01234567890123456789012345678
2	0
2	1
2	2
2	3
2	4
2	5
2	6
2	7
2	8
2	9
3	0
3	1
3	2
े २	2
2 2	1
2	4 5
ວ ວ	6
ა ი	0
3	1
3	8
3	9
4	
4	
4	
4	
4	
4	
4	
4	
4	
4	
5	0
5	
5	
5	
5	
5	
5	
5	7
5	י פ
5 F	o 9
່ ວ	3

Table S3. YLLs of confirmed H7N9 cases

Age group	Life expectancy at age(Male)	Life expectancy at age(Female)	Number of deaths (Male)	Number of deaths (Female)	YLL(years)*
AGE<1	74.05	77.17	0	0	0.00
AGE1-4	74.01	77.14	0	0	0.00
AGE5-9	70.16	73.29	0	0	0.00
AGE10-14	65.23	68.36	0	0	0.00
AGE15-19	60.31	63.43	0	0	0.00
AGE20-24	55.48	58.57	0	0	0.00
AGE25-29	50.74	53.77	1	0	50.74
AGE30-34	45.99	48.98	0	1	48.98
AGE35-39	41.29	44.21	1	1	85.50
AGE40-44	36.57	39.42	0	0	0.00
AGE45-49	31.96	34.70	1	0	31.96
AGE50-54	27.41	30.06	1	1	57.47
AGE55-59	23.04	25.57	2	0	46.09
AGE60-64	18.88	21.23	6	2	155.73
AGE65-69	15.03	17.15	2	1	47.20
AGE70-74	11.71	13.50	4	1	60.35
AGE75-79	9.00	10.39	3	1	37.40
AGE80-84	6.65	7.68	3	1	27.64
AGE85-89	4.95	5.58	5	0	24.74
AGE90-94	2.99	3.40	1	0	2.99
AGE95-99	2.15	2.37	0	0	0.00
AGE100+	1.53	1.67	0	0	0.00
Total			30	9	676.78

*YLL = years of life lost due to premature mortality.

Table S4. YLDs of confirmed H7N9 cases

Table S4. YLDs of confirmed H7N9 cases				
	Disability weight [*]	Number of cases	Duration of disability(years)	YLD(years) [¶]
Mild	0.005	25	0.025	0.003
Severe	0.21	95	0.052	1.038
Unknown(moderate)	0.053	11	0.038	0.022
Total		131	0.115	1.064

*Disability weight: Institute for Health Metrics and Evaluation (IHME),GBD 2010 Disability Weights

[¶]YLD = years lived with disability.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
ĥ
7
1
8
9
10
11
12
12
13
14
15
16
17
18
19
20
20 24
21
22
23
13456789101234156789011234156789011234567890112334567890011233456789001123333333333333333333333333333333333
25
26
27
20
28
29
30
31
32
33
3/
25
30
36
37
38
39
40
41
41
42 43
44
45
46
47
48
40
50
51
52
53
54
55
56
57
58
59
60

60

1

Table S5. Potential poultry-industry losses of eight non-affected adjacent provinces

Potential affected provinces	Cost of live-poultry sales(10 ⁴ CNY)	Market-stall leases (10 ⁴ CNY)	Total cost (10 ⁴ CNY)	Total cost (10 ⁴ USD)
Guangxi	126671.29	2623.68	129294.97	20687.20
Guizhou	13793.65	256.32	14049.97	2248.00
Chongqing	32341.22	2904.12	35245.34	5639.25
Hubei	76709.59	2097.12	78806.71	12609.07
Shaanxi	7859.11	213.72	8072.83	1291.65
Shanxi	9571.87	473.46	10045.33	1607.25
Hebei	78872.43	1340.10	80212.53	12834.01
Tianjin	11426.38	582.00	12008.38	1921.34
Total cost (10 ⁴ CNY)	357245.56	10490.52	367736.08	58837.77
Total cost (10 ⁴ USD)	57159.29	1678.48	58837.77	9414.04



Calculating the burden of disease of avian-origin H7N9 infections in China

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-004189.R1
Article Type:	Research
Date Submitted by the Author:	22-Nov-2013
Complete List of Authors:	Qi, Xiaopeng; Chinese Center for Disease Control and Prevention, National center for public health surveillance and information services Jiang, Dong; Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Wang, Hongliang; The 2nd Affiliated Hospital of Harbin Medical University, ICU Zhuang, Dafang; Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Ma, Jiaqi; Chinese Academy of Sciences, Ma, Jiaqi; Chinese Academy of Sciences, Ma, Jiaqi; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Fu, Jingying; University of Chinese Academy of Sciences, Qu, Jingdong; The 2nd Affiliated Hospital of Harbin Medical University, Su, Yan; School of Public Health, Harbin Medical University, Yu, Shicheng; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Meng, Yujie; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Huang, Yaohuan; Institute of Geographical Sciences and Natural Resources Research, Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Huang, Yaohuan; Institute of Geographical Sciences and Natural Resources Research, Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Wang, Guohua; School of Public Health, Harbin Medical University, Xu, Ke; College of Geoscience and Surveying Engineering, China University of Mining & Technology(Beijing), Zhang, Qun; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Wan, Ming; Chinese Center for Disease Control and Prevention, National Center for Public Health Surveillance and Information Services Gau, Ming; Chinese Center for Disease Control and Prevention, National Center
Primary Subject Heading :	Health economics
Secondary Subject Heading:	Public health

1 2	
3	Keywords: Burden of diseases, H7N9, HEALTH ECONOMICS
4 5	
6 7	
8	SCHOLAR ONE [™]
9 10	Manuscripts
11 12	
13	
14 15	
16 17	
18	
19 20	
21	
22 23	
24 25	
26	
27 28	
29 30	
31	
32 33	
34 35	
36	
37 38	
39	
40 41	
42 43	
44	
45 46	
47 48	
49	
50 51	
52 53	
54	
55 56	
57	
58 59	
60	

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Calculating the burden of disease of

avian-origin H7N9 infections in China

Xiaopeng Qi^{1*}, Dong Jiang^{2*}, Hongliang Wang^{3*}, Dafang Zhuang^{2*}, Jiaqi Ma^{1*}, Jingying Fu^{2,4}, Jingdong Qu³, Yan Sun⁵, Shicheng Yu¹, Yujie Meng¹, Yaohuan Huang², Lanfang Xia¹, Yingying Li¹, Yong Wang², Guohua Wang⁵, Ke Xu⁶, Qun Zhang¹, Ming Wan¹, Xuemei Su¹, Gang Fu¹, George F Gao⁷

*These authors contributed equally to this work

- National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing, China,
- 2 State Key Laboratory of Resources and Environmental Information System, Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing, China,
- 3 The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China,
- 4 University of Chinese Academy of Sciences, Beijing, China,
- 5 School of Public Health, Harbin Medical University, Harbin, China,
- 6 College of Geoscience and Surveying Engineering, China University of Mining & Technology(Beijing), Beijing, China,
- 7 Office of the Director, Chinese Center for Disease Control and Prevention, Beijing, China

Correspondence to:

Dr XP Qi, National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing 102206, China

<u>qixp@chinacdc.cn</u>

Tel: +86-1058900453

Fax: +86-1058900453

and

Prof G F Gao, Office of the Director, Chinese Center for Disease Control and Prevention, Beijing 102206, China

gaofu@chinacdc.cn

Tel: +86-1058900211 Fax: +86-1058900211

Keywords Burden of diseases, H7N9, Health Economics Word count 3664

Calculating the burden of disease of

avian-origin H7N9 infections in China

Abstract

Objective A total of 131 cases of avian-originated H7N9 infection have been confirmed in China mainland from February to May 2013. We calculated the overall burden of H7N9 cases in China as of May 31, 2013 to provide an example of the comprehensive burden of disease in the 21st century from an acute animal-borne emerging infectious disease.

Design We present an accurate and operable method for estimating the burden of H7N9 cases in China. The main drivers of economic loss were identified. Costs were broken down into direct (outpatient and inpatient examination and treatment) and indirect costs (cost of disability-adjusted life years [DALYs] and losses in the poultry industry), which were estimated based on field surveys and china statistical yearbook.

Setting Models were applied to estimate the overall burden of H7N9 cases in China.

Participants One-hundred and thirty-one laboratory-confirmed H7N9 cases by May 31, 2013.

Outcome measure Burden of H7N9 cases including direct and indirect losses.

Results The total direct medical cost was 16,422,535 CNY (2,627,606 USD). The mean cost for each patient was 10,117 CNY(1,619 USD) for mild patients, 139,323 CNY(22,292 USD) for severe cases without death, and 205,976 CNY(32,956 USD) for severe cases with death. The total cost of DALYs was 17,356,561 CNY(2,777,050 USD). The poultry industry losses amounted to 7.75 billion CNY(1.24 billion USD) in 10 affected provinces and 3.68 billion CNY(0.59 billion USD) in eight non-affected adjacent provinces.

Conclusions The huge poultry industry losses followed live poultry markets closing down and poultry slaughtering in some areas. Though the proportion of direct medical losses and DALYs losses in the estimate of H7N9 burden was small, the medical costs per case were extremely high (particularly for addressing the use of modern medical devices). A cost-effectiveness assessment for the intervention should be conducted in a future study.

Article summary

Strengths and limitations of this study

• This study is the first in which comprehensive methods were applied to identify the main drivers of economic losses and estimate the burden of disease due to H7N9 infection

including direct costs (medical cost) and indirect costs (death, disability, and poultry-industry losses);

• This study had some limitations. The estimate of medical costs was based on a model and second-hand data, not on the original costs of patients with H7N9. The burden of H7N9 may have been underestimated, as the ongoing costs of existing cases and new cases after May 2013 were underreported and other losses involved in the livestock-production chain were not included in our study.

BMJ Open

Introduction

A novel avian-origin influenza A (H7N9) virus has caused severe disease in humans in China since February 2013. The high number of new cases within a short period and the high case fatality rate have caused public panic and attracted global attention. Some patient's families undertook large medical costs. According to the literature, exposure to live poultry could be an important risk factor for human infection with H7N9.¹⁻⁵ As a result, closing down the live-poultry markets and slaughtering the poultry were the main interventional measures in the affected areas of China. These interventions played an important role in disease prevention but also caused serious losses to the poultry industry.

The introduction of the novel virus led to numerous investigations of its origin, its genes, clinical symptoms, laboratory testing, treatment and transmission ⁶⁻⁸; however, the burden of human infection with H7N9 has not yet been measured. It is important to estimate the overall burden of disease (BOD) due to H7N9 in China because this virus is new to humans and could cause a global pandemic in the future. The Global Burden of Disease (GBD) 2010 study presents a comprehensive methodological framework for death and disability loss estimation and has had a pronounced impact on the BOD estimate ^{9 10}. In this study, we identified the main drivers of economic loss and summarized the direct and indirect costs of human H7N9 infection. We present an accurate and operable approach for estimating the overall burden of emerging infectious diseases and provide evidence on the cost effectiveness of H7N9 prevention and control. We also set up a BOD estimate example for any animal-borne infectious disease, particularly with the introduction of modern medical devices.

Methods

Case category definition

The confirmed human H7N9 infections were divided into mild and severe cases based on the "Diagnostic and treatment protocol for human infections with avian influenza A (H7N9) (2nd edition, 2013)".¹¹ Mild cases presented with influenza-like illness, whereas severe cases developed quickly and presented with severe pneumonia, usually accompanied by severe complications and organ failure. Severe illness was divided into "severe without death" and "severe with death". The 11 H7N9 cases of unknown status were classified as "unknown without death".

Data source

Data on the 131 confirmed H7N9 cases by the end of May 31, 2013 came from China Information System for Diseases Control and Prevention and included basic information on the onset of illness, epidemiology and emergency event reporting. Disability-adjusted life years (DALYs) were calculated based on two published sources. The World Health Organization (WHO) provided a table of life expectancy by age for China in 2011,¹² whereas the Institute for Health Metrics and Evaluation (IHME) published the GBD 2010, including the GBD 2010 Disability Weights .¹³ Disability weights of general infectious disease (acute episode for mild, moderate, and severe) were adopted from IHME based on clinician's suggestions of symptoms from H7N9 cases

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

that were more severe than the general infectious disease cases. The 2012 per capita gross domestic product (GDP), which was used to calculate the cost of lost lives and the cost of disability, was obtained from the National Bureau of Statistics of China.

Poultry production and trade data from 27 prefectures with confirmed H7N9 cases, including live-poultry sales, dates of live-market closings, and market-stall volumes were collected from field surveys, *local livestock-breeding year book*¹⁴ and the *Chinese Commodities Trading-Market Statistics Yearbook 2012*.¹⁵ Data were gathered from the 10 affected provinces and 8 unaffected adjacent provinces. These data were used to estimate poultry-industry losses.

Analysis framework for the burden of confirmed H7N9 cases

We constructed a framework for the BOD analysis (Figure 1). We described the confirmed H7N9 cases as mild, severe without death, severe with death, and unknown without death and examined the spatiotemporal and population characteristics of these cases. Based on the case category and characteristics of case spatiotemporal distribution, costs were broken down into direct medical costs (outpatient and inpatient examination and treatment) and indirect costs (death, disability and poultry-industry losses). To calculate the DALYs attributable to H7N9, the H7N9-specific years of life loss due to premature mortality (YLLs) and years lived with disability (YLDs) were computed and summed. An intensive analysis of poultry-industry losses would be complex and would require time-consuming field surveys. Indirect effects may lag behind. In this study, we considered only the poultry industry losses caused from the closing of live-poultry markets and the large-scale slaughtering of poultry.

Statistical analysis

Descriptive statistics were used to summarize the epidemiological characteristics of the cases. The distribution of confirmed H7N9 cases by week was also extracted by creating two standard deviational ellipses (covering 95% of the points while calculating the standard deviation of the x-coordinates and y-coordinates from the mean center to define the axes of the ellipse) to summarize the spatial spread of confirmed H7N9 cases (central tendency, dispersion, and directional trends). If the number of cases in 1 week was less than three, those cases were not included in the calculation.

The methods for estimating direct medical costs are traditionally classified into two broad approaches: bottom-up (micro-costing) and top-down (macro-costing).^{16 17} In general, the bottom-up approach usually results in a higher but more accurate estimate.¹⁸ In our study, we used the bottom-up approach to estimate direct medical costs. Four cost drivers were extracted: cost of outpatient and inpatient examinations in the ward, cost of examinations in intensive-care units (ICUs), cost of treatment, and other costs (including medical consumables, charge for sickbed, general care services, checkup fee, etc.). A cost formula was constructed for each driver, as depicted in Table 1. The cost per patient was estimated by experienced hospital financial officers and hospital doctors. The mean number of days (ICU stay, hospital stay, and days of treatment) was estimated from the epidemiological data. The number of patients for each driver was derived from a previous publication.⁶ The professional's experience was also considered for some items

Page 7 of 51

BMJ Open

that were not included in our surveillance system. Costs for the category "unknown without death" were assumed to be moderate and were set as the average of the costs of mild cases and severe cases without death.

The YLLs for confirmed H7N9 cases in China were calculated from the sum of the number of fatal cases (n) in 5-year age groups (i) multiplied by the remaining expected life span (e) based on the age of death for that age group:¹⁹ (formula 1)

$$YLLs = \sum n_i \times e_i \tag{1}$$

The Chinese life-expectancy table from WHO 2011 was used to estimate the burden of H7N9 in YLLs.

The YLDs were calculated by multiplying the duration of illness (t) by the disability weights (w) accumulated over all H7N9 cases (d) for each health outcome (j): (formula 2)

$$\mathbf{YLDs} = \sum \mathbf{d}_{j} \times \mathbf{t}_{j} \times \mathbf{W}_{j} \tag{2}$$

As H7N9 is a relatively new infectious disease and the health status of patients after discharge is unknown, we calculated the YLDs only as general acute episodes of infectious disease during the hospital stay. Disability weights were assigned as infectious disease (mild, moderate, and severe acute episodes).¹³

DALYs were calculated by adding YLLs to morbidity and disability, expressed in YLD (formula 3).

$$DALYs = YLLs + YLDs$$
(3)

An estimate of the cost of one DALY was based on the traditional human-capital approach for per-capita GDP (formula 4). Production capability weights were calculated considering the different production capabilities at different ages. The following weights were used according to the literature: 0.15 at age 0–14 years, 0.75 at age 15–44 years, 0.8 at age 45–59 years, and 0.1 at age 60+ years.²⁰

Cost of DALYs = DALYs \times per-capita GDP \times weight of production capability (4)

As mentioned above, direct poultry-industry losses (PIL) can be calculated using formula 5:

$$PIL = L_1 + L_2 \tag{5}$$

where L_1 is the loss from poultry slaughter and L_2 is the loss from the closing of live-poultry markets, which includes lost sales of live poultry (L_{21}) and fees for market-stall leases (L_{22}). A cost formula was constructed for the estimate of poultry industry loses (Table 2).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Results

Epidemiological characteristics of case categories

A total of 131 confirmed H7N9 cases in 10 provinces in China were mapped as individual points based on detailed addresses (Figure 2). Most (81%) of the patients were located in Jiangsu, Shanghai, and Zhejiang Provinces. Most of the cases (73% or above) in the ten provinces were severe. There were 25 mild cases, 56 severe cases without death, 39 severe cases with death, and 11 unknown cases without death in China through May 31, 2013.

Figure S1 shows the rate, direction, and scope of H7N9 spread. Each ellipse covers 95% of the incident cases for 1 week. The location of the first week of H7N9 onset was in Shanghai. Over the next few weeks, the epidemic spread to Jiangsu and Zhejiang Provinces and continued to grow. The virus spread quickly from the northwest to the north and south regions.

The onset of most H7N9 cases was relatively clustered. Within the total event timeframe (February 19–May 21), 74% of the cases were infected between March 28–April 17 (Figure S2). Severe cases with death were found in the initial and intermediate stages. The median age of patients with confirmed H7N9 virus infection was 61 years (range, 3–91 years). Severe symptoms tended to occur in older people. The median age of patients who were severely ill without death was 60 years, whereas the median age of patients who were severely ill with death was 69 years. The number of mild cases was distributed in all age groups < 80 years (Figure S3).

Direct medical costs for confirmed H7N9 cases

After the confirmed H7N9 cases occurred in China, the patient's clinical manifestations, examinations, and treatments were published,⁶ which allowed us to estimate direct medical costs using a cost model. We separated the examination data into examinations conducted in the ward and examinations conducted in the ICU, as the latter were more frequent. The main treatments for confirmed H7N9 cases were selected. Three main factors were considered in our cost formula: cost per day, number of days, and number of patients. For the cost-per-day estimation, we selected a Grade-III Class-A hospital (general large-scale hospital in China). Cost per day was obtained from the hospital financial officers and hospital doctors based on the average cost of patients with the same treatments from January 1, 2013 to May 31, 2013 in this hospital (Table S1). Differences in costs among the regions in China were approximately 10%.

The mean number of days and number of cases were estimated from a subset of the investigated cases (Table 3). Data regarding hospital stay were available for 11 of the 25 mild cases, 19 of the 56 severe cases without death, and 19 of the 39 severe cases with death. The mean length of stay was 9 days for mild cases, 18 days for severe cases without death, and 20 days for severe cases with death. Data on the duration of ICU stay were available for 10 of the 56 severe cases without death and 11 of the 39 severe cases with death. Severe cases without death stayed in the ICU for a mean of 12 days, whereas severe cases with complications was equal to the length of the ICU stay, although complications might occur incrementally. The mean duration of treatments

BMJ Open

was estimated based on a subset of investigated patients, except for glucocorticoids and intravenous immune globulin, for which estimates were obtained from professional experience. Treatment for complications required drugs and examinations in addition to the treatments listed above. Treatment was described for 111 confirmed H7N9 cases, along with the proportion of patients who received each treatment.⁸ We assumed that the proportions were generalizable to all cases because it covered 85% of cases.

Table S2 is a summary of all direct medical costs. The total cost for all 131 patients with confirmed H7N9 virus infection was 16,422,535 CNY (2,627,606 USD). The mean cost per patient was 10,117 CNY (1,619 USD) for mild patients, 139,323 CNY (22,292 USD) for severe cases without death, and 205,976 CNY (32,956 USD) for severe cases with death. The mean cost per day was 1,124 CNY (180 USD) for a mild case, 8,293 CNY (1,327 USD) for a severe case without death, and 8,978 CNY (1,437 USD) for a severe case with death. As the severity of the illness increased, the costs increased correspondingly.

Cost of DALYs for H7N9

A total of 39 deaths from confirmed H7N9, including 30 males and 9 females, were reported from the National Health and Family Planning Commission of China by May 31, 2013. See Table S3 for more details on the number of cases in each age group. The total YLLs were 676.89. There were 131 H7N9 cases, including 25 mild cases, 95 severe cases, and 11 of unknown category (assumed to be moderate). The YLD calculations were based on the case category. Total YLDs were 1.064 (Table S4). DALYs combined the time lived with disability and the time lost due to premature mortality; thus, DALYs were 677.848 for all confirmed H7N9 patients. We adopted 2012 per-capita GDP for the 10 provinces and estimated the cases adjusted per capita GDP (65,655 CNY or 10,505USD). By calculating the weight of production capability for each age group, we obtained the average weight of production capability to be 0.39 for all confirmed H7N9 cases. The total cost of DALYs was 17,356,561 CNY (2,777,050 USD) according to formula 4.

Poultry-industry losses

Poultry-industry losses were estimated for three categories (Figure 3): 1) 27 prefectures with confirmed H7N9 cases (region 1, brown in Figure 3), 2) 10 affected provinces (region 2, yellow in Figure 3), and 3) eight non-affected adjacent provinces (region 3, shadowed in Figure 3).

Three types of losses were calculated for region 1: losses from poultry slaughter, lost live poultry sales, and fees for market-stall leases. In the 10 affected provinces (region 2), in addition to the losses in region 1, the losses arose mainly from closing down live-poultry markets in each province. These two losses were then summed to estimate poultry-industry losses caused by H7N9 outbreaks. Most of the main live-poultry markets in the affected provinces (Figure 3) were obtained from Google Earth; the retail locations were excluded.

Poultry-industry losses in eight non-affected adjacent provinces (region 3) were also calculated as potential economic losses. The direct poultry-industry losses of 27 prefectures for the H7N9 cases are described in detail in Table 4.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

The cost of closing down live-poultry markets includes the lost live poultry sales and fees for market-stall leases. The cost of lost live poultry sales was calculated according to the daily live-poultry sales, the cost per animal (assumed to be 10 CNY or 1.6USD in this study), and the number of days the market was closed. The cost of market-stall leases was calculated based on the average lease per stall per day in the corresponding city, the number of stalls, and the number of days the market was closed in each city. The cost of poultry slaughter was obtained from the number of poultry slaughtered and the cost per animal. The number of days the market was closed was counted through May 31 because only one confirmed H7N9 case had occurred since then. The total poultry-industry losses in the 10 affected provinces, including 27 prefectures with H7N9 cases, are listed in Table 5. The poultry-industry losses of each province are presented in Figure S4.

China's poultry industry suffered direct losses amounting to 7.75 billion CNY(1.24USD) from when the first case of H7N9 was confirmed through May 31, 2013. Losses from the live-poultry trade accounted for 98% of the total losses. Although it had only a few H7N9 cases, Shandong Province ranked first in losses among all 10 provinces at 1.81 billion CNY(0.29USD); Jiangsu, Henan, and Anhui ranked next with 1.28 billion CNY(0.20USD), 1.15 billion CNY(0.18USD), and 1.14 billion CNY(0.18USD), respectively. These provinces have large poultry markets. Zhejiang Province had the highest number of confirmed cases; however, the losses in that region were not very high, as the sales of live poultry were lower. Strict prevention and control measures, such as daily cleaning of the market, weekly disinfection of the market, and monthly closings of the live market were conducted in Guangdong Province, which reported no H7N9 cases until May 31, 2013 during the emergency response. These prevention and control measures affected the poultry industry. For this reason, the poultry-industry losses in Guangdong Province are also given in Table 5.

Due to timely control measures, the H7N9-affected regions were limited to 27 prefectures in ten provinces in China. In this study, the potential economic risks were also calculated for the eight non-affected adjacent provinces (region 3, shadowed in Figure 3). Table S5 shows that the potential losses to the poultry industry in those regions amounted to 3.6 billion CNY(0.58USD).

Discussion

This study was based on illness severity and spatiotemporal aspects of the recent avian-origin influenza A (H7N9) infection. We assumed that cases of the same severity resulted in similar medical costs. Therefore, mild cases, severe cases without death, severe cases with death, and unknown cases without death were estimated separately by calculating the mean number of days, number of cases, and cost per day.

Compared to the poultry-industry losses, direct medical losses and DALY losses were relatively small. To a large extent, the small number of patients in the H7N9 outbreak in China was due to quick and effective intervention, which prevented a pandemic.²¹ The estimate of direct medical costs and DALY costs, particularly the mean cost per patient and mean cost per day for

BMJ Open

different case categories, can be used to guide those counties in which no cases occurred during prevention and control of H7N9. DALY per H7N9 case (5,176 DALYs per 1,000 cases) was much higher than most of other respiratory infectious diseases though DALYs per 100,000 population (2.23 DALYs based on affected county population) were lower than most of the infectious diseases according to the 2010 GBD study.²² A comparison to outbreaks of other infectious diseases (with similar clinical symptoms) was also considered in this report. The healthcare cost per SARS patient in Beijing was 17,150 CNY (1,886 USD), whereas the average medical cost per H7N9 patient was 125,363 CNY (20,058 USD) because of the higher fatality rate of H7N9 patients and use of more expensive modern medical devices.²³

As of the end of May, China's poultry industry suffered direct losses amounting to 7.75 billion CNY(1.24USD), including the cost of closing live poultry markets and slaughtering poultry in the ten affected provinces. Poultry-industry losses were estimated at three levels: 27 prefectures with confirmed H7N9 cases, 10 affected provinces, and 8 non-affected adjacent provinces. The outbreak of H7N9 may reduce the demand for poultry products in other regions of China due to public perception. These effects were not considered in this study. The cost of closing down the live-poultry markets and the cost of poultry slaughter were calculated as direct poultry-industry losses. We assumed that the cost per animal was 10 CNY(1.6USD) and the date for the end of closing the live-poultry markets was May 31, 2013 because there has been few confirmed H7N9 cases, with the lost sales of live poultry constituting the majority of that amount. Strict prevention and control measures have been enacted in Guangdong Province, which had few reported H7N9 cases. This finding will be significant for similar cases in the future. Due to timely control measures, the effects of the outbreak were limited to 27 prefectures in 10 provinces in China.

Our study had several limitations. First, there were 11 confirmed H7N9 cases without death whose case categories were unknown. The cost estimate for these unknown patients was replaced by the average cost of mild and severe cases without death. Second, in the cost model, some of the data (e.g., mean number of days of extracorporeal membrane oxygenation for severe without death cases) were obtained from a small proportion of investigated cases, which could result in an estimation bias. Third, the direct medical cost did not include opportunity cost,²⁴ the cost that is incurred because a limited resource is used to treat a preventable disease and cannot therefore be used to treat another disease.²⁵ The medical practitioner's salary, research funding, and loss of working time for family numbers of patients with H7N9 were excluded from our study. Fourth, estimates of direct medical costs per day might show large differences for specific cases because the drug cost could grow considerably if imported and nutritional drugs were used. We considered only the average severity for patients in the ward and ICU. Fifth, 17 patients were still in the hospital on May 28, 2013 according to the literature.²⁶ The mean numbers of days in the ward and ICU for severe cases and their fatality rate were thus underestimated. Some of the mild cases may not have been reported, which also resulted in underestimating the cost. Sixth, we considered only direct losses from closing down live-poultry markets and large-scale poultry slaughter, which could be estimated accurately and quickly. This estimate was useful for early control and decision-making; however, other losses involved in the livestock-production chain, such as increased breeding costs, poultry seeding, the prices of poultry meat and eggs, and the decreased production of poultry-feather industries, should be considered in further studies.²⁷

In conclusion, we present a rapid, operable, and accurate framework for estimating the burden of human infections from H7N9. This framework could be used in a BOD analysis of future H7N9 or similar outbreaks. The results including direct and indirect costs provide fundamental information for researchers and public and policy makers to support timely and effective interventions. Future study may focus on the cost-effectiveness analysis of poultry industry close down, earlier diagnosis and effective treatments of patients based on more detailed investigation information.

Data sharing

No additional data available.

Contributorship

All authors participated in the conception and design of the report. XQ and GFG designed and supervised the study, and applied the grants. XQ, DJ, HW, DZ, JM, JF, JQ, YS, GW, KX collected data. XQ, DJ, JF, SY, YM, YH, LX, YL, YW, XS and GF analyzed data. QZ, MW, LX and YL took literature search, XQ and DJ drafted the manuscript, and all authors contributed to review and revision and have seen and approved the final version.

Competing Interests

We declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.



References

- Li Q, Zhou L, Zhou M, et al. Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. N Engl J Med 2013.
- 2. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. *Lancet* 2013;381:1916-25.
- 3. Bao CJ, Cui LB, Zhou MH, et al. Live-animal markets and influenza A (H7N9) virus infection. *N Engl J Med* 2013; 368: 2337-39.
- 4. Wu Y, Gao GF. Lessons learnt from the human infections of avian-origin influenza A H7N9 virus: live free markets and human health. *Sci China Life Sci* 2013; 56: 493-4.
- 5. Li J, Yu X, Pu X, et al. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human. *Sci China Life Sci* 2013; 56: 485-92.
- 6. Liu D, Shi W, Shi Y, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. *Lancet* 2013;381:1926-32.
- Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368:1888-97.
- Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013;368:2277-85.
- 9. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. *Lancet* 2012;380:2063-6.
- 10. Murray CJ, Frenk J, Piot P, et al. GBD 2.0: a continuously updated global resource. *Lancet* 2013.
- Diagnostic and treatment protocol for human infections with avian influenza A (H7N9)(2n d edition, 2013), 2013. Available: <u>http://www.moh.gov.cn/mohgjhzs/s7952/201304/98ceede1da f74a45b1105f18c4e23ece.shtml</u> Accessed 10 June 10 2013.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

- 12. Life expectancy: Life tables China, 2011. Available: <u>http://apps.who.int/gho/data/view.main.6</u> 0340?lang=en Accessed 10 June 2013.
- GBD 2010 Disability Weights 2010. Available: <u>http://ghdx.healthmetricsandevaluation.org/gl</u> obal-burden-disease-study-2010-gbd-2010-data-downloads Accessed 10 June 2013.
- 14. China Animal Industry Yearbook. Beijing: China Agricultural Press, 2012.
- Statistical Yearbook of China Commodity Exchange Market. Beijing: Foreign Economy Statistics Division, National Statistics Bureau; Market Operation and Consumer Promotion Divison of Ministry of Commerce; Information Department of Commerce Association of China, 2012.
- 16. Lipscomb J, Yabroff KR, Brown ML, et al. Health care costing: data, methods, current applications. *Med care* 2009;47:S1-6.
- 17. Allorto NL, Clarke DL, Thomson SR. A cost model case comparison of current versus modern management of burns at a regional hospital in South Africa. *Burns* 2011;37:1033-7.
- Clement Nee Shrive FM, Ghali WA, Donaldson C, et al. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. *Health Econ* 2009;18:377-88.
- 19. Polinder S, Haagsma JA, Stein C, et al. Systematic review of general burden of disease studies using disability-adjusted life years. *Popul Health Metr* 2012;10:21.
- Du L, Wang J, Luo B, et al. Research on disease burden of SARS patients in Guangzhou city. *Chinese Journal of Public Health* 2007;23:379-81.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

- 21. Yu H, Wu J, Cowling B, et al. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. *The Lancet* 2013.
- Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2197-223.
- Xiao F, Chen BW, Wu YF, et al. Analysis on the cost and its related factors of clinically confirmeds severe acute respiratory syndrome cases in Beijing. *Zhonghua liuxingbingxue zazhi* 2004;25:312-6.
- 24. O'Shea C. Opportunity cost. Australian Family Physician 2011;40:261-61.
- 25. Kong V, Aldous C, Handley J, et al. The cost effectiveness of early management of acute appendicitis underlies the importance of curative surgical services to a primary healthcare programme. *Ann R Coll Surg Engl* 2013;95:280-4.
- 26. Yu H, Cowling BJ, Feng L, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. *The Lancet* 2013.
- 27. FAO. Highly pathogenic avian influenza in Mexico (H7N3) a significant threat to poultr y production not to be underestimated. *Empres Watch*: EMPRES WATCH, 2012. Available: http://www.fao.org/docrep/016/an395e/an395e.pdf Accessed 15 June 2013.

BMJ Open

Figure legends

Figure 1. Framework for calculating the burden of confirmed H7N9 cases. (Figure 1 describes the analytical route of direct and indirect costs, which were integrated into the overall burden of confirmed H7N9 cases. The framework was drawn using the Microsoft Office Visio 2003 software.)

Figure 2. Spatial distribution of the 131 confirmed H7N9 cases. (Figure 2 presents the spatial distribution of the 131 confirmed H7N9 cases by severity in China. Mild, severe without death, severe with death, and unknown without death cases are distinguished by different colors. The points are mapped based on the coordinates of the addresses. Areas with a high density of cases are magnified in the top right corner. The map was drawn using the ArcGIS 10.0 software.)

Figure 3. Three regions for poultry-industry loss estimates. (Figure 3 presents estimated poultry-industry losses for three categories including 27 prefectures, 10 affected provinces, and 8 non-affected adjacent provinces. Points represent most of the main live-poultry markets, which were obtained from Google Earth excluding the retail locations. The map was drawn using the ArcGIS 10.0 software.)

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

6

Table 1. Formula for calculating direct medical costs.

Cost	Formula
Cost of examination for outpatient and	
inpatient in ward (laboratory and radiology)	Cost per patient × number of patients
Cost of examination in ICU	
(laboratory and radiology)	Cost per day \times mean number of days of ICU stay \times number of patients
Cost of treatment	
Antiviral	Cost per day \times mean number of days \times number of patients
Antibiotics	Cost per day \times mean number of days \times number of patients
Other drugs	Cost per day \times mean number of days \times number of patients
Glucocorticoids	Cost per day \times mean number of days \times number of patients
Intravenous immune globulin	Cost per day \times mean number of days \times number of patients
	Cost per day \times mean number of days of hospital stay \times number of
Oxygen therapy	patients
ICU care	Cost per day \times mean number of days of ICU stay \times number of patients
ICU monitor	Cost per day \times mean number of days of ICU stay \times number of patients
Mechanical ventilation	
Noninvasive	Cost per day \times mean number of days \times number of patients
Invasive	Cost per day \times mean number of days \times number of patients
Artificial-liver-support-system therapy	Cost per day \times mean number of days \times number of patients
Continuous renal-replacement therapy	Cost per day × mean number of days × number of patients
Extracorporeal membrane oxygenation (ECMO)	Cost per day \times mean number of days \times number of patients
Complications	
ARDS	Cost per day \times mean number of days of ICU stay \times number of patients
Shock	Cost per day \times mean number of days of ICU stay \times number of patients
Acute kidney injury	Cost per day \times mean number of days of ICU stay \times number of patients
Rhabdomyolysis	Cost per day \times mean number of days of ICU stay \times number of patients
Other costs [§]	Cost per day ×mean number of days of hospital stay × number of patients

⁸Other costs include medical consumables, charge for sickbed, general care services, checkup fees, etc.

Cost	Formula
Cost of poultry slaughter (L1)	Cost per animal × number of poultry killed
Cost of closing live-poultry markets (L ₂)	
Cost of live-poultry sales(L21)	Live-poultry sales per day \times cost per animal \times number of days
Cost of market-stall leases (L22)	Cost of lease per stall per day \times number of stalls \times number of days

Table 2. Formula for calculating poultry-industry losses.

Table 3. Driver measurement.

⊿0

g,	Mean number of days (no. of cases estigated/total cases)		Severe without de	atn	Severe with death		Unknown w	ithout death	D.C
U stay		Number of cases	Mean number of days (no. of cases investigated/total cases)	Number of cases	Mean number of days (no. of cases investigated/total cases)	Number of cases	Mean number of days [¶]	Number of cases	Reference proportion of patients (%)*
•	9 (11/25)	25	18 (19/56)	55	20 (19/39)	38	14	11	98.
reatment	0	0	12 (10/56)	55	16 (11/39)	38	6	7	76
Antiviral	7 (3/25)	24	7 (20/56)	54	11 (11/39)	38	7	11	97
Antibiotics	8 (4/25)	17	11 (21/56)	40	14 (16/39)	28	9	8	71
Other drugs	9 (11/25)	25	12 (10/56)	55	16 (11/39)	38	11	11	98
Glucocorticoids	0	0	7 [§]	43	7 [§]	30	4	8	62
Intravenous immune globulin	0	0	5 [§]	37	5 [§]	26	3	7	53
Oxygen therapy Mechanical ventilation	9 (11/25)	25	18 (19/56)	56	20 (19/39)	39	9	11	100
Noninvasive	0	0	9 (7/56)	19	3 (6/39)	13	5	4	27
Invasive	0	0	8 (7/56)	41	10 (15/39)	28	4	8	58
Artificial-liver-support-system	0	0	4 [§]	11	4 [§]	7	2	2	15
erapy Continuous renal-replacement erapy	0	0	7 [§]	18	7 [§]	13	4	4	26
Extracorporeal membrane ygenation (ECMO)	0	0	6(1/56)	12	7 (2/39)	9	3	2	18
Complications									
ARDS	0	0	12 (10/56)	50	16 (11/39)	35	6	10	71
Shock	0	0	12 (10/56)	18	16 (11/39)	13	6	4	26
Acute kidney injury	0	0	12 (10/56)	11	16 (11/39)	8	6	2	16
Rhabdomyolysis	0	0	12 (10/56)	7	16 (11/39)	5	6	1	9
her costs	9 (11/25)	25	18 (19/56)	55	20 (19/39)	38	14	11	98

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1	
2	
3	
1	
4	
5	
6	
7	
ß	
0	
9	
10	
11	
12	
12	
13	
14	
15	
16	
10	
17	
18	
19	
20	
20	
21	
$2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 2 \\ 11 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 12 \\ 23 \\ 24 \\ 25 \\ 27 \\ 28 \\ 9 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 11 \\ 11 \\ 11 \\ 11 \\ 11$	
23	
24	
27	
20	
26	
27	
28	
20	
29	
30	
31	
32	
33	
24	
34	
35	
36	
37	
38	
30	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
50	
57	
58	
59	
60	

Affected	Affected			Cost of closin	g live-poultry markets		Cost of
provinces (number of cases)	prefectures (number of cases)	Date	Live-poultry sales per day (10 ⁴)	Number of days	Cost of live-poultry sales(10 ⁴ CNY)	Market-stall leases (10 ⁴ CNY)	poultry slaughter (10 ⁴ CNY)
Beijing (2)	Beijing (2)	4.13	3.00	49	1470.00	6.93	0.50
Shanghai (32)	Shanghai (32)	4.05	11.94	57	6805.80	1703.16	20.54
Jiangsu (29)	Wuxi (4)	4.09	12.87	53	6821.10	527.40	0.40
	Yancheng (1)	4.15	8.18	47	3844.60	387.11	5.00
	Nanjing (12)	4.06	8.91	56	4989.60	567.84	8.00
	Zhenjiang (1)	4.09	8.55	53	4531.50	342.12	0.31
	Suzhou (7)	4.08	17.73	54	9574.20	265.03	0.01
	Yangzhou (1)	4.15	11.52	47	5414.40	180.17	0.20
	Xuzhou (1)	4.24	14.80	38	5624.00	380.30	0.10
	Changzhou (1)	4.11	8.94	51	4559.40	167.71	1.30
	Suqian (1)	4.02	10.14	60	6084.00	200.00	0.10
Zhejiang (45)	Huzhou (12)	4.11	6.14	51	3131.40	269.79	0.70
	Shaoxing (1)	4.22	5.31	40	2124.00	585.14	10.00
	Hangzhou (29)	4.15	12.48	47	5865.60	1200.20	24.66
	Jiaxing (2)	4.19	6.97	43	2997.10	1565.77	10.00
	Wenzhou (1)	4.21	7.02	41	2878.20	49.78	0.50
Auhui (4)	Bozhou (1)	4.09	2.89	53	1531.70	100.33	10.00
	Chuzhou (3)	3.30	6.19	63	3899.70	65.01	0.72
Fujian (5)	Longyan (1)	5.07	6.73	25	1682.50	77.40	0.82
	Fuzhou (4)	4.29	6.61	33	2181.30	287.76	100.00
Jiangxi (6)	Nanchang (5)	4.26	12.62	36	4543.20	45.72	0.10
	Yichun (1)	4.29	10.46	33	3451.80	14.09	0.08
Henan (4)	Zhoukou (1)	4.16	13.59	46	6251.40	18.28	1.60
	Kaifeng (1)	4.15	9.22	47	4333.40	14.81	1.80
	Zhengzhou (2)	4.15	9.01	47	4234.70	20.68	3.90
Hunan (2)	Shaoyang (2)	4.28	7.80	34	2652.00	70.10	100.00
Shandong (2)	Zaozhuang (2)	4.24	21.20	38	8056.00	52.36	0.66
Total cost (10 ⁴ C	CNY)	128999.59			-		
Total cost (10 ⁴ U	JSD)*	20639.93					

Note: 'Date' indicates the date on which the live-poultry markets were closed; 'days' is the number of days the live-poultry markets remained closed.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Affected provinces	Cost of live-poultry sales (10 ⁴ CNY)	Market-stall leases (10 ⁴ CNY)	Cost of poultry slaughter (10 ⁴ CNY)	Total cost (10 ⁴ CNY)	Total cost (10 ⁴ USD)
Beijing	14553.98	291.06	0.5	14845.54	2394.59
Shanghai	6805.8	1703.16	20.54	8529.5	1375.81
Jiangsu	124485.53	3181.5	25.62	127692.66	20596.83
Zhejiang	29982.14	2444.4	45.36	32471.9	5237.72
Anhui	113309.59	1113.01	11.52	114434.12	18458.22
Fujian	16723.29	509.04	100.82	17333.15	2795.84
Jiangxi	40832.88	255.36	0.18	41088.42	6627.56
Henan	114473.97	73.09	7.3	114554.36	18477.62
Hunan	32301.37	433.25	100	32834.62	5296.22
Shandong	180421.92	402.76	0.66	180825.34	29167.13
Guangdong	88827.4	1808.59	99.36	90735.35	14635.61
Total cost (10 ⁴ CNY)	762717.86	12215.21	411.87	775344.94	125063.14
Total cost (10 ⁴ USD)	123026.39	1970.31	66.43	125063.14	2394.59

Table 5. Total poultry-industry losses in the 10 affected provinces.

Note: Date on which the live-poultry markets were closed varied among cities/counties. In Table 5, the dates when the first case of H7N9 was confirmed were adopted for estimating the total amount of poultry-industry losses in each affected province.

BMJ Open

<u>Calculating the burden of disease of</u>
avian-origin H7N9 infections in China
Xiaopeng Qi ^{1*} , Dong Jiang ^{2*} , Hongliang Wang ^{3*} , Dafang Zhuang ^{2*} , Jiaqi Ma ^{1*} , Jingying Fu ^{2,4} , Jingdong Qu ³ , Yan Sun ⁵ , Shicheng Yu ¹ , Yujie Meng ¹ , Yaohuan Huang ² , Lanfang Xia ¹ , Yingying Li ¹ , Yong Wang ² , Guohua Wang ⁵ , Ke Xu ⁶ , Qun Zhang ¹ , Ming Wan ¹ , Xuemei Su ¹ , Gang Fu ¹ , George F Gao ⁷
*These authors contributed equally to this work
1 National Center for Public Health Surveillance and Information Services, Chinese Center for
Disease Control and Prevention, Beijing, China,
2 State Key Laboratory of Resources and Environmental Information System, Institute of
Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences,
Beijing, China,
3 The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China,
4 University of Chinese Academy of Sciences, Beijing, China,
5 School of Public Health, Harbin Medical University, Harbin, China,
6 College of Geoscience and Surveying Engineering, China University of Mining &
Technology(Beijing), Beijing, China,
7 Office of the Director, Chinese Center for Disease Control and Prevention, Beijing, China
Correspondence to:
Dr XP Qi, National Center for Public Health Surveillance and Information Services, Chinese
Center for Disease Control and Prevention, Beijing 102206, China
gixp@chinacdc.cn
<u>Tel: +86-1058900453</u>
<u>Fax: +86-1058900453</u>
and
Prof G F Gao, Office of the Director, Chinese Center for Disease Control and Prevention, Beijing
<u>102206, China</u>
gaoru@cninacdc.cn
<u>Tel: +86-1058900211</u>
<u>Fax: +86-1058900211</u>
Keywords Burden of diseases, H7N9, Health Economics
Word count 3747

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Calculating the burden of disease of

avian-origin H7N9 infections in China

Abstract

Objective In China, A total of 134-131 cases of avian-originoriginated H7N9 infections infection have been confirmed in China mainland since-between February to May 2013. We aimed tocalculate calculated the overall burden of H7N9 cases in China as of May 31, 2013 to giveprovide an example of the comprehensive burden of disease in the 21st century of from an acute animal-borne emerging infectious disease.

Design We present an accurate and operable method for estimating the burden of H7N9 cases in China. The main drivers of economic loss were identified. Costs were broken down into direct (outpatient and inpatient examination and treatment) and indirect costs (cost of <u>DALY_disability-adjusted life years [DALYs]</u> and losses in the poultry industry), which were estimated based on field surveys and china statistical yearbook-and statistical data.

Setting Models were applied to estimate the overall burden of H7N9 cases in China.

Participants 131 Laboratory <u>One-hundred and thirty-one laboratory-</u>confirmed H7N9 cases (excluding one Taiwan case) by May 31, 2013.

Outcome measure Burden of H7N9 cases including direct and indirect losses.

Results The total direct <u>medialmedical</u> cost was 16,422,535 CNY (2,627,606 USD). The mean cost for each patient was 10,117 CNY(1,619 USD) for mild <u>patientpatients</u>, 139,323 CNY-22,292 USD for severe cases without death, and 205,976 CNY(32,956 USD) for severe cases with death. The DALYs were 677.848 and tThe total cost of DALYs was 17,356,561 CNY(2,777,050 USD). Poultry-industry losses were estimated on three levels: 27 prefectures with cases, 10 affected provinces, and eight8 non-affected adjacent provinces, including the costs<u>cost</u> of closing the live poultry market and slaughter. The poultry industry losses amountamounted to 7.75 billion CNY(1.24 billion USD) in 10 affected provinces and 3.68 billion CNY(0.59 billion USD) in eight non-affected adjacent provinces.

Conclusions The huge poultry industry losses followed live poultry markets closing down and poultry slaughtering in some areas. Though the proportion of direct medical losses and DALYs losses in the estimate of H7N9 burden was small, The number of H7N9 incidence cases decreased accompanied by<u>in conjunction with closing of</u> the live-poultry markets and slaughtering the poultry. However, the medical costs per case and DALY per case-were extremely high (esp.particularly for addressing the use of modern medical <u>device</u>). Cost<u>devices</u>). A cost-effectiveness

assessment for the intervention needs to should be done conducted in a future study.

Article summary

Strengths and limitations of this study

- This study is the first (to our knowledge) in which comprehensive methods were applied to identifiedidentify the main drivers of economic losses and estimate the burden of disease due to H7N9 infection including direct costcosts (medical cost) and indirect costcosts (death, disability, and poultry-industry losses);
- This study hashad some limitations. Estimation The estimate of the-medical costcosts was based on thea model and second-hand data, not on the H7N9 patients' original costs- of patients with H7N9. The burden of H7N9 might bemay have been underestimated since, as the ongoing costs of existing cases and new cases after May 2013, were underreported cases and other losses involved in the livestock-production chain were not included in our study.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Introduction

 A novel avian-origin influenza A (H7N9) virus has caused severe disease in humans in China since February 2013. The high number of new cases within a short period and the high case fatality rate have caused public panic and attracted global attention. It was also reported from media that some patients' Some patient's families undertook large medical costs. According to the literature, exposure to live poultry could be an important risk factor for human infection with H7N9. ¹⁻³⁻⁵_As a result, closing-_down the live-poultry markets and slaughtering the poultry were the main interventioninterventional measures in the affected areas inof China. These interventions played an important role in disease prevention, but-on the other hand, also caused serious losses to the poultry industry.

The introduction of the novel virus led to numerous investigations on theof its origin of the virus, its genes, clinical symptoms, laboratory testtesting, treatment and transmission $\frac{46-68}{5}$; however, the burden of human infection with H7N9 has not yet been measured. It is important to estimate the overall burden of disease (BOD) due to H7N9 in China because this virus is new into humans and could cause a global pandemic in the future. The Global Burden of Disease (GBD) 2010 study presents a comprehensive methodological framework for death and disability loss estimation and has had a pronounced impact on the estimation of BOD estimate $\frac{7-9.810}{10}$. In this study, we identified the main drivers of economic lossesloss and summarized the direct and indirect costs of human H7N9 infection. We aimed to present an accurate and operable approach for estimating the overall burden of emerging infectious diseases and to-provide evidence on the cost effectiveness of H7N9 prevention and control. We also aim to-set up a BOD estimationestimate example for any animal-borne infectious diseases, esp-disease, particularly with the introduction of modern medical deviced vices.

Methods

Case category definition

The confirmed human <u>H7N9</u> infections of H7N9 were divided into mild and severe cases based on the "Diagnostic and treatment protocol for human infections with avian influenza A (H7N9) (2nd edition, 2013)"...)".⁹-¹¹ Mild cases presented with influenza-like illness (ILI), while, whereas severe cases developed quickly and presented with severe pneumonia, usually accompanied by severe complications and organ failure. Severe illness was divided into "severe without <u>death'death</u>" and "severe with <u>death'.death</u>". The 11 H7N9 cases of unknown status were classified as "unknown without <u>death'.death"</u>.

Data source

Data on the 131 confirmed <u>H7N9</u> cases of H7N9 by the end of May 31, 2013 came from China's information Information system System for disease Diseases control Control and preventionPrevention and included basic information on the onset of illness, epidemiology and emergency event reporting. Disability-adjusted life years (DALYs) were calculated based on two other published sources. The World Health Organization (WHO) provided a table of life

BMJ Open

expectancy by age for China in 2011,⁴⁰⁻¹² while whereas the Institute for Health Metrics and Evaluation (IHME) published the Global Burden of Disease (GBD) 2010, including the GBD 2010 Disability Weights .⁴⁴-¹³ Disability weights of general infectious disease (acute episode for mild, moderate, and severe) were adopted from IHME based on the clinician's suggestion though the suggestions of symptoms offrom H7N9 cases that were more severe than the general infectious disease cases. The 2012 per-capita gross domestic product (GDP), which was used to calculate the cost of lost lives or and the cost of disability, was obtained from the National Bureau of Statistics of China.

Poultry production and trade data $\frac{\text{from 27} \text{from 27}}{\text{prefectures with confirmed H7N9 cases,}}$ including live-poultry sales, dates of live-market closings, and market-stall volumes, were collected from field surveys, *local livestock-breeding year book* $\frac{^{+2}-^{14}}{^{-14}}$ and the $\frac{^{+}Chinese}{^{-14}}$ *Commodities Trading-Market Statistics Yearbook* $\frac{2012^{+2}2012}{^{-12}}$.¹³ Data were gathered from the ten10 affected provinces and eight8 unaffected adjacent provinces. These data were used to estimate poultry-industry losses.

Analysis framework offor the burden of confirmed H7N9 cases

We constructed a framework for the BOD analysis (Figure 1). We described the confirmed H7N9 cases category as mild, severe without death, severe with death, and unknown without death and examined the spatiotemporal and population characteristics of these cases. Based on the case category and characteristics of case spatiotemporal distribution, costs were broken down into direct medical costs (outpatient and inpatient examination and treatment) and indirect costs (death, disability and poultry-industry losses). To calculate the DALYs attributable to H7N9, the H7N9-specific years of life losst due to premature mortality (YLLs) and years lived with disability (YLDs) were computed and then summed. An intensive analysis of poultry-industry losses would be complex and would require time-consuming field surveys. Meanwhile, indirectIndirect effects may lag behind. In this paperstudy, we considered only the poultry industry losses caused from the closing of live-poultry markets and the large-scales laughterscale slaughtering of poultry.

Statistical analysis

Descriptive statistics were used to summarize the <u>epidemiologic_pidemiological</u> characteristics of the cases. The distribution of confirmed H7N9 cases by week was also extracted by creating two standard deviational ellipses (covering 95% of the points while calculating the standard deviation of the x-coordinates and y-coordinates from the mean center to define the axes of the ellipse) to summarize the spatial spread of confirmed H7N9 cases (central tendency, dispersion, and directional trends). If the number of cases in <u>one1</u> week was less than three, those cases were not included in the calculation.

The methods for estimating direct medical costs are traditionally classified into two broad approaches: bottom-up (micro-costing) and top-down (macro-costing).^{44+5<u>1617</u> In general, the bottom-up approach usually results in a higher but more accurate estimate.^{46<u>18</u>} In our study, we used the bottom-up approach to estimate the-direct medical costs. Four cost drivers were extracted: cost of outpatient and inpatient examinations in <u>the</u> ward, cost of <u>examinationexaminations</u> in}

 intensive-care units (ICUs), cost of treatment, and other costs (including medical consumables, charge for sickbed, general care services, checkup fee, etc)...). A cost formula was constructed for each driver, as depicted in Table 1. The cost per patient was estimated by experienced hospital financial officers and hospital doctors. The mean number of days (ICU stay, hospital stay, and days of treatmentstreatment) was estimated from the epidemiologicepidemiological data. The number of patients for each driver was derived from a previous publication.⁶ Professionals' experiences were The professional's experience was also considered for some items that were not included in our surveillance system. The costsCosts for the category "unknown without death'death" were assumed to be moderate and were set as the average of the costs of mild cases and severe cases without death.

The YLLs for confirmed H7N9 cases in China were calculated from the sum of the number of fatal cases (n) in 5-year age groups (i) multiplied by the remaining expected life span (e) based on the age of death for that age group: 47-9 (formula 1)

$$YLLs = \sum \mathbf{n}_i \times \mathbf{e}_i \tag{1}$$

To estimate the burden of H7N9 in YLLs, the The Chinese life-expectancy table from WHO 2011 was used to estimate the burden of H7N9 in YLLs.

The YLDs were calculated by multiplying the duration of illness (t) by the disability weights (w) accumulated over all H7N9 cases (d) for each health outcome (j): (formula 2)

$$YLDs = \sum d_j \underline{\times}^{\underline{*}} t_j \underline{\times}^{\underline{*}} W_j$$
(2)

As H7N9 is a relatively new infectious disease and the health <u>statestatus</u> of patients after discharge is unknown, we calculated the YLDs only as general acute episodes of infectious disease during the hospital stay. Disability weights were assigned as infectious disease (mild, moderate, and severe acute episodes).⁺⁺¹³

The DALYs are were calculated by adding YLLs to morbidity and disability, expressed in YLD (formula 3).

$$DALYs = YLLs + YLDs$$
(3)

An <u>estimationestimate</u> of the cost of one DALY was based on the traditional human-capital approach for per-capita GDP (formula 4). <u>ConsideringProduction capability weights were</u> <u>calculated considering</u> the different production capabilities at different ages, the weights ofproduction capability were calculated. The following weights were used according to the literature: 0.15 at age 0–14 years, 0.75 at age 15–44 years, 0.8 at age 45–59 years, and 0.1 at age 60+.+ <u>years</u>.

Cost of DALYs = DALYs $\underline{*x}$ per-capita GDP $\underline{*x}$ weight of production capability (4)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

As mentioned above, direct poultry-industry losses (PIL) can be calculated using formula 5:

$$PIL = L_1 + L_2 \tag{5}$$

where L_1 is the loss from poultry slaughter and L_2 is the loss from the closing of live-poultry markets, which includes the lost sales of live poultry (L_{21}) and fees for market-stall leases (L_{22}). A cost formula was constructed for the estimation estimate of poultry industry loses (Table 2).

Results

EpidemiologicEpidemiological characteristics for different of case categories

A total of 131 confirmed H7N9 cases in ten01 provinces in China were mapped as individual points based on detailed addresses (Figure 2). Most (81%) of the patients were located in the Jiangsu, Shanghai, and Zhejiang provincesProvinces. Most of the cases (73% or above) in the ten provinces were severe. There were 25 mild cases, 56 severe cases without death, 39 severe cases with death, and 11 unknown cases without death in China through May 31, 2013.

Figure S1 is the presentation of shows the rate, direction, and scope of the H7N9 spread. Each ellipse covers 95% of the incident cases for one1 week. The location of the first week of H7N9 onset was in Shanghai. Over the next few weeks, the epidemic extended spread to the Jiangsu and Zhejiang provinces Provinces and continued to grow. The virus spread quickly spread from the northwest to the north and south regions.

The onset of most H7N9 cases was relatively clustered. Within the total event timeframe (24February 19–54May 21), 74% of the cases were infected between 34March 28–44–April 17 (Figure S2). Severe cases with death were found in the initial and intermediate stages. The median age of patients with confirmed H7N9 virus infection was 61 years (range, 3-to-91_years). Severe symptoms tended to occur in older people. The median age of patients who were severely ill without death was 60 years, whilewhereas the median age of patients who were severely ill with death was 69 years. The number of mild cases was distributed onin all age groups under 80 years (Figure S3).

Direct medical costs offor confirmed H7N9 cases

After the confirmed H7N9 cases occurred in China, the <u>patients'patient's</u> clinical manifestations, examinations, and treatments were published,⁶ which allowed us to estimate-the direct medical costs using a cost model. We separated the examination data into examinations conducted in <u>the</u> ward and examinations <u>conducted in the</u> ICU, as the latter were more frequent. The main treatments for confirmed H7N9 cases were selected. In our cost formula, three <u>Three</u> main factors were considered <u>in our cost formula</u>: cost per day, number of days, and number of patients. For the cost-per-day estimation, we selected a Grade-III Class-A hospital (general large-scale hospital in China). <u>CostsCost</u> per day <u>werewas</u> obtained from the hospital financial officers and hospital doctors based on the average <u>costscost</u> of patients with <u>the</u> same treatments from <u>Jan.January</u> 1, 2013 to May 31, 2013 in this hospital (Table S1). Differences in costs among

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

the regions in China were approximately 10%.

The mean number of days and number of cases were estimated from a subset of the investigated cases (Table 3). Data regarding hospital stay were available for 11 of the 25 mild cases, 19 of the 56 severe cases without death, and 19 of the 39 severe cases with death. The mean length of stay was 9 days for mild cases, 18 days for severe cases without death, and 20 days for severe cases with death. Data on the duration of ICU stay were available for ten10 of the 56 severe cases without death and 11 of the 39 severe cases with death. Severe cases without death stayed in the ICU for a mean of 12 days, while whereas severe cases with death stayed for a mean of 16 days. We assumed that the mean hospital stay of severe cases with complications was equal to the length of the ICU stay, although complications might occur incrementally. The mean durationsduration of different treatments lasting were also was estimated based on a subset of investigated patients, except for glucocorticoids and intravenous immune globulin, for which estimates were obtained from professionals' experiences.professional experience. Treatment for complications required drugs and examinations in addition to the treatmenttreatments listed above. Treatment was described for 111 confirmed H7N9 cases, along with the proportion of patients who received each treatment.⁶⁻⁸ We assumed that the proportions were generalizable to all cases because it covered 85% of cases.

Table S2 is thea summary of all of the direct medical costs. The total cost for all 131 patients with confirmed H7N9 virus infection was 16,422,535 CNY (2,627,606 USD). The mean cost for eachper patient was 10,117 CNY (1,619 USD) for mild patientpatients, 139,323 CNY (22,292USD292 USD) for severe cases without death, and 205,976 CNY (32,956USD956 USD) for severe cases with death. The mean cost per day was 1,124 CNY (180 USD) for mild cases, 8,293 CNY (1,327 USD) for severe cases without death, and 8,978 CNY (1,437 USD) for severe cases with death. As the severity of the illness increased, the costs increased correspondingly.

Cost of DALYs onfor H7N9

A total of 39 deaths from confirmed H7N9, including 30 males and 9 females, were reported from the National Health and Family Planning Commission of China by 31-May 31, 2013. For See Table S3 for more details on the number of cases in each age group, see Table S3. The total YLLs were 676.89. There were 131 H7N9 cases, including 25 mild cases, 95 severe cases, and 11 of unknown category (assumed to be moderate). The YLD calculations were based on the case category. The total Total YLDs were 1.064 (Table S4). The DALYs combine combined the time lived with disability and the time lost due to premature mortality; thus, the DALYs were 677.848 for all confirmed H7N9 patients. We adopted 2012 per-capita GDP offor the ten10 provinces and estimated the cases adjusted per-capita GDP (65,655 CNY or 10,505USD). By calculating the weight of production capability for each age group, we gotobtained the average weight of production capability to be 0.39 for all confirmed H7N9 cases. The total cost of DALYs was 17,356,561 CNY (2,777,050 USD) according to the formula 4.

Poultry-industry losses

BMJ Open

In region1, three<u>Three</u> types of losses were calculated <u>for region 1</u>: losses from poultry slaughter, lost <u>sales of live</u> poultry <u>sales</u>, and fees for market-stall leases. In the <u>ten10</u> affected provinces (region 2), in addition to the losses in <u>region1region 1</u>, the losses <u>arose</u> mainly arose from the closing- down-of live-poultry markets in each province. These two losses were then summed to estimate poultry-industry losses caused by H7N9 outbreaks. Most of the main live-poultry markets in the affected provinces (presented in Figure 3) were obtained from Google Earth; the retail locations were excluded.

Poultry-industry losses in eight non-affected adjacent provinces (region 3) were also calculated as potential economic losses. The direct poultry-industry losses of 27 prefectures for the H7N9 cases are described in detail in Table 4.

The cost of closing-_down live-poultry markets includes the lost <u>sales of live poultry sales</u> and fees for market-stall leases. The cost of lost <u>sales of live poultry sales</u> was calculated according to the daily live-poultry sales, the cost per animal (assumed to be 10 CNY <u>or 1.6USD</u> in this <u>paper)study</u>), and the number of days the market was closed. The cost of market-stall leases was calculated based on the average lease per stall per day in the corresponding city, the number of stalls, and the number of days the market was closed in each city. The cost of poultry slaughter was obtained from the number of poultry slaughtered and the cost per animal. The number of days the market was closed was counted through May 31 because there have been only one confirmed H7N9 <u>cases_case had occurred</u> since then. The total poultry-industry losses in the <u>ten10</u> affected provinces, including 27 prefectures with H7N9 cases, are listed in Table 5. The poultry-industry losses of each province are presented in Figure S4.

In general, China's poultry industry suffered direct losses amounting to 7.75 billion CNY(<u>1.24USD</u>) from when the first case of H7N9 was confirmed through May 31, 2013. Losses from the live-poultry trade accountaccounted for 98% of the total losses. Although it had only a fewH7N9few H7N9 cases, Shandong Province ranked first in losses among all ten<u>10</u> provinces at 1.81 billion CNY(<u>0.29USD</u>); Jiangsu, Henan, and Anhui ranked next; with 1.28 billion CNY(<u>0.20USD</u>), 1.15 billion CNY(<u>0.18USD</u>), and 1.14 billion CNY(<u>0.18USD</u>), respectively. These provinces have large poultry markets. Zhejiang Province had the highest number of confirmed cases; however, the losses in that region were not very high, as the sales of live poultry were lower. Strict prevention and control measures, such as daily cleaning of the market, weekly disinfection of the market, and monthly closings of the live market; were conducted in Guangdong Province, which reported no H7N9 cases till <u>31until</u> May <u>31</u>, 2013 during the emergency response. Meanwhile, these These prevention and control measures affected the poultry industry. For this reason, the poultry-industry losses in Guangdong Province are also given in Table 5.

Due to timely control measures, the H7N9-affected regions were limited to the-27 prefectures in ten provinces in China. In this study, the potential economic risks were also calculated for the eight non-affected adjacent provinces (region 3, shadowed in Figure 3). Table S5 shows that the potential losses to the poultry industry in those regions amountamounted to 3.6 billion CNY(0.58USD).

Discussion

 This study was based on illness severity and spatiotemporal aspects of the recent avian-origin influenza A (H7N9) infectionsinfection. Our results indicate that there were clusters of patients infected with H7N9 in China. Of the 131 patients, 81% resided in the Jiangsu, Shanghai and, or Zhejiang provincesProvinces, and 74% were infected during the period of 3/March 28 4/_April_17. Patients over≥ 50 -years of _age accounted for 72% of the total, and 95 patients (73.1%) were diagnosed as severe cases. The fatality rate of confirmed H7N9 cases in China was 26.9%. We assumed that cases of the same severity resulted in similar medical costs. Therefore, mild cases, severe cases without death, severe cases with death, and unknown cases without death were estimated separately by calculating the mean number of days, number of cases, and cost per day. The mean cost per patient was 8,880 CNY (1,421 USD) for mild cases, 144,788 CNY (23,166 USD) for severe cases without death-and184, and 184, 211 CNY (29,474 USD) for severe cases with death. The totalTotal direct medical costcosts for all patients waswere 15,963,935 CNY (2,554,230 USD). The DALYs, which were determined from the YLLs and YLDs, were 677.848 years for all confirmed H7N9 cases. The total cost of the DALYs was 17,356,561 CNY (2,777,050 USD) according to the average GDP per capita and average weight of production capability.

Compared to the poultry-industry losses, the-direct medical losses and DALY losses were relatively small. To a large extent, the small number of patients in the H7N9 outbreak in China was due to quick and effective interventionsintervention, which prevented a pandemic.²¹ The estimation<u>estimate</u> of direct medical <u>costcosts</u> and DALY <u>cost</u>, <u>especiallycosts</u>, <u>particularly</u> the mean cost per patient and mean cost per day for different case categories, can be used to guide those counties in which H7N9 <u>no</u> cases <u>did not occur in theoccurred during</u> prevention and control of H7N9. DALY per H7N9 case (<u>51765,176</u> DALYs per <u>10001,000</u> cases) was much higher than-the<u>most of</u> other respiratory infectious diseases according to the 2010 GBD study though DALYs per 100,000 population (2.23 DALYs based on affected county population) were lower than most of the infectious diseases according to the 2010 GBD study.¹⁹ ²² A comparison to outbreaks of other infectious diseases (with similar clinical symptomsymptoms) was also considered in this report. The health carehealthcare cost per SARS patient in Beijing was 17,150 CNY (1,886USD)-while<u>886 USD</u>), whereas the average medical cost per H7N9 patient was 99,691 CNY_(15,951 USD) because of the higher fatality rate of H7N9 patients and <u>use of</u> more expensive modern medical device had been useddevices.²⁰²³

As of the end of May, <u>China'sChina's</u> poultry industry suffered direct losses amounting to 7.75 billion CNY(<u>1.24USD</u>), including the cost of closing live-poultry markets and slaughtering poultry in the ten affected provinces. Poultry-industry losses were estimated at three levels: 27 prefectures with confirmed H7N9 cases, 10 affected provinces, and <u>eight8</u> non-affected adjacent provinces. The outbreak of H7N9 may reduce the demand for poultry products in other regions of

China, due to public <u>perceptionsperception</u>. These effects were not considered in this <u>paperstudy</u>. The cost of closing-down the live-poultry markets and the cost of poultry slaughter were calculated as direct poultry-industry losses. We assumed that the cost per animal <u>iswas</u> 10 CNY(<u>1.6USD</u>) and the date for the end of closing the live-poultry markets was May 31, 2013 because there has been <u>only onefew</u> confirmed H7N9 cases since then. Losses from the live-poultry industry <u>accountaccounted</u> for 98% of the total losses, with the lost sales of live poultry constituting the majority of that amount. Strict prevention and control measures have been enacted in Guangdong Province, which had few reported <u>H7N9</u> cases-of H7N9. This finding will be significant for similar cases in the future. Due to timely control measures, the effects of the outbreak were limited to 27 prefectures in <u>ten10</u> provinces in China.

Our study had several limitations. First, there were 11 confirmed H7N9 cases without death whose case categories were unknown. The cost estimationestimate for these unknown patients was replaced by the average cost of mild and severe cases without death. Second, in the cost model, some of the data (e.g., mean number of days of ECMOextracorporeal membrane oxygenation for severe without death cases) were obtained from a small proportion of investigated cases, which could result in an estimation bias. Third, the direct medical cost did not include opportunity cost,²⁴-²⁴ the cost that is incurred because a limited resource is used to treat a preventable disease and cannot therefore be used to treat another disease.^{22,25} The medical practitioners' practitioner's salary, research funding, and loss of working time for family numbers of patients on with H7N9 were excluded infrom our study. Fourth, estimations estimates of the direct medical eostcosts per day might show large differences for specific cases because the drug cost could grow considerably if imported and nutritional drugs were used. We considered only the average severity for patients in the ward and in-ICU. Fifth, 17 patients were still in the hospital byon May 28, 2013 according to the literature.^{23,26} The mean numbers of days in the ward and in ICU offor severe cases and their fatality rate were thus underestimated. And someSome of the mild cases may not behave been reported, which also resulted in the underestimation of underestimating the cost. Sixth, in this paper, we considered only direct losses from the closing down of live-poultry markets and large-scale poultry slaughter, which could be estimated accurately and quickly. This estimationisestimate was useful for early control and decision-making; however, other losses involved in the livestock-production chain, such as increased breeding costs, poultry seeding, the prices of poultry meat and eggs, and the decreasingdecreased production of poultry-feather industries, should be considered in further studies.²⁴²⁷

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

In conclusion, we presentedpresent a quickrapid, operable, and accurate framework for estimating the burden of human infections withfrom H7N9. This framework could be used in thea BOD analysis of future H7N9 or similar outbreaks. The results, including direct and indirect costs, provide fundamental information for researchers, the and public and policy makers to support timely and effective interventions. Future study may focus on the cost-effectiveness analysis of poultry industry close down, earlier diagnosis and effective treatments of patients based on more detailed investigation information.

References

- Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. <u>N Engl J Med The New England journal of medicine</u> 2013.
- Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. *Lancet* 2013;381:1916-25.
- Bao CJ, Cui LB, Zhou MH, Hong L, Gao GF, Wang H. Live-animal markets and influenza A (H7N9) virus infection. <u>N Engl J MedThe New England journal of medicine</u> 2013; 368: 2337-39.
- 4. Wu Y, Gao GF. Lessons learnt from the human infections of avian-origin influenza A H7N9 virus: live free markets and human health. *Sci China Life Sci* 2013; 56: 493-4.
- Li J, Yu X, Pu X, Xie L, Sun Y, Xiao H, et al. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human. *Sci China Life Sci* 2013; 56: 485-92.
- 46. Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. *Lancet* 2013;381:1926-32.
- 57. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. <u>N Engl J MedThe New England journal of medicine</u> 2013;368:1888-97.
- Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. <u>N Engl J Med The New England journal of medicine</u> 2013;368:2277-85.
- 79. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. *Lancet* 2012;380:2063-6.
- <u>\$10</u>. Murray CJ, Frenk J, Piot P, Mundel T. GBD 2.0: a continuously updated global resource. *Lancet* 2013.
- 9<u>11</u>. Diagnostic and treatment protocol for human infections with avian influenza A (H7N9) (2nd edition, 2013), 2013. Available: <u>http://www.moh.gov.cn/mohgjhzs/s7952/201304/98ceede</u> 1daf74a45b1105f18c4e23ece.shtml Accessed 10 June 10 2013.
- 1012.
 Life expectancy: Life tables China, 2011. Available: http://apps.who.int/gho/data/view.m

 ain.60340?lang=en
 Accessed 10 June 2013.
- 44<u>13</u>. GBD 2010 Disability Weights 2010. Available: <u>http://ghdx.healthmetricsandevaluation.</u> org/global-burden-disease-study-2010-gbd-2010-data-downloads Accessed 10 June 2013.
- 4214. China Animal Industry Yearbook. Beijing: China Agricultural Press, 2012.
- 1315. Statistical Yearbook of China Commodity Exchange Market. Beijing: Foreign Economy Statistics Division, National Statistics Bureau; Market Operation and Consumer Promotion Divison of Ministry of Commerce; Information Department of Commerce Association of China, 2012.
- 14<u>16</u>. Lipscomb J, Yabroff KR, Brown ML, Lawrence W, Barnett PG. Health care costing: data, methods, current applications. *Medical care* 2009;47:S1-6.
- 45<u>17</u>. Allorto NL, Clarke DL, Thomson SR. A cost model case comparison of current versus modern management of burns at a regional hospital in South Africa. *Burns : journal of the International Society for Burn Injuries* 2011;37:1033-7.
- 4618. Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs

BMJ Open

	m
	≌
	Ś
	_ -
	Ο
	ğ
	Φ
	±
	ร
	÷
	ō
	듲
	≌
	S
	₹
	ä
	~
	ß
	°.
	1
	<u> </u>
	<u> </u>
	<u></u>
	8
	×
	9
	⊇.
	0
	ğ.
	Ψ.
	<u>.</u>
	2
	ç
	5
	ų
	õ
	ò
	4
	2
	3
	້
	Ч
	<u> </u>
	1
	~
	Ś
	Щ.
	7
	ā
	2
	<u> </u>
	2
	2
	4
	· .
	ē.
	0
	Š
	nwc
	oluMc
	ownloa
	ownload
	ownloaded
	ownloaded :
	ownloaded fru
	ownloaded fror
	ownloaded from
	ownloaded from h
	ownloaded from htt
	BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http:
	ownloaded from http://
	ownloaded from http://b
	ownloaded from http://bm
	ownloaded from http://bmjc
	ownloaded from http://bmjop
	ownloaded from http://bmjope
	ownloaded from http://bmjopen
	ownloaded from http://bmjopen.t
	ownloaded from http://bmjopen.bn
	ownloaded from http://bmjopen.bmj
	ownloaded from http://bmjopen.bmj.c
	ownloaded from http://bmjopen.bmj.co
	ownloaded from http://bmjopen.bmj.com
	ownloaded from http://bmjopen.bmj.com/
	ownloaded from http://bmjopen.bmj.com/ ou
	ownloaded from http://bmjopen.bmj.com/ on
	ownloaded from http://bmjopen.bmj.com/ on A
	ownloaded from http://bmjopen.bmj.com/ on Ap
•	ownloaded from http://bmjopen.bmj.com/ on April
	ownloaded from http://bmjopen.bmj.com/ on April 1
	ownloaded from http://bmjopen.bmj.com/ on April 19
	ownloaded from http://bmjopen.bmj.com/ on April 19,
	ownloaded from http://bmjopen.bmj.com/ on April 19, 2v
•	ownloaded from http://bmjopen.bmj.com/ on April 19, 202
-	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024
-	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 i
	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 by
•	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 by o
	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 by gu
	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 by gue
	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 by gues
	ownloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
-	://bmjopen.bmj.com/ on April 19, 2024 by guest.
-	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.
-	://bmjopen.bmj.com/ on April 19, 2024 by guest.
	://bmjopen.bmj.com/ on April 19, 2024 by guest.

gross-costing approaches. Health EconHealth economics 2009;18:377-88.
47 <u>19</u> . Polinder S, Haagsma JA, Stein C, Havelaar AH. Systematic review of general burden of
disease studies using disability-adjusted life years. Popul Health MetrPopulation health metrics
2012;10:21.
1820. Du L, Wang J, Luo B, Pan B, Chen J, Zhou R, et al. Research on disease burden of SARS
patients in Guangzhou city. Chinese Journal of Public Health 2007;23:379-81.
21. Yu H, Wu J, Cowling B, Liao Q, Fang V, Zhou S, et al. Effect of closure of live poultry markets
on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. The
Lancet 2013.
4922. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
2023. Xiao F, Chen BW, Wu YF, Wang YX, Han DM. Analysis on the cost and its related factors of
clinically confirmeds severe acute respiratory syndrome cases in Beijing. Zhonghua liu xing bing-
xue za zhi = Z honghua liuxingbingxue zazhi 2004;25:312-6.
2424. O'Shea C. Opportunity cost. Australian Family Physician 2011;40:261-61.

- 2225. Kong V, Aldous C, Handley J, Clarke D. The cost effectiveness of early management of acute appendicitis underlies the importance of curative surgical services to a primary healthcare programme. <u>Ann R Coll Surg Engl Annals of the Royal College of Surgeons of England</u> 2013;95:280-4.
- 23<u>26</u>. Yu H, Cowling BJ, Feng L, Lau EHY, Liao Q, Tsang TK, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. *The Lancet* 2013.
- 2427. FAO. Highly pathogenic avian influenza in Mexico (H7N3) a significant threat to p oultry production not to be underestimated. *Empres Watch*: EMPRES WATCH, 2012. Avail able:<u>http://www.fao.org/docrep/016/an395e/an395e.pdf</u> Accessed 15 June 2013.






Figure 1. Framework for calculating the burden of confirmed H7N9 cases. (Figure 1 describes the analytical route of direct and indirect costs, which were integrated into the overall burden of confirmed H7N9 cases. The framework was drawn using the Microsoft Office Visio 2003 software.)




Figure 2. Spatial distribution of the 131 confirmed H7N9 cases. (Figure 2 presents the spatial distribution of the 131 confirmed H7N9 cases by severity in China. Mild, severe without death, severe with death, and unknown without death cases are distinguished by different colors. The points are mapped based on the coordinates of the addresses. Areas with a high density of cases are magnified in the top right corner. The map was drawn using the ArcGIS 10.0 software.)




Figure 3. Three regions for poultry-industry loss estimates. (Figure 3 presents estimated poultry-industry losses for three categories including 27 prefectures, 10 affected provinces, and 8 non-affected adjacent provinces. Points represent most of the main live-poultry markets, which were obtained from Google Earth excluding the retail locations. The map was drawn using the ArcGIS 10.0 software.)

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

6

Table 1. Formula for calculating direct medical costs.

Cost	Formula
Cost of examination for outpatient and	
inpatient in ward (laboratory and radiology)	Cost per patient × number of patients
Cost of examination in ICU	
(laboratory and radiology)	Cost per day \times mean number of days of ICU stay \times number of patients
Cost of treatment	
Antiviral	Cost per day × mean number of days × number of patients
Antibiotics	Cost per day × mean number of days × number of patients
Other drugs	Cost per day × mean number of days × number of patients
Glucocorticoids	Cost per day × mean number of days × number of patients
Intravenous immune globulin	Cost per day × mean number of days × number of patients
	Cost per day × mean number of days of hospital stay × number of
Oxygen therapy	patients
ICU care	Cost per day × mean number of days of ICU stay × number of patients
ICU monitor	Cost per day × mean number of days of ICU stay × number of patients
Mechanical ventilation	
Noninvasive	Cost per day × mean number of days × number of patients
Invasive	Cost per day × mean number of days × number of patients
Artificial-liver-support-system therapy	Cost per day × mean number of days × number of patients
Continuous renal-replacement therapy	Cost per day × mean number of days × number of patients
Extracorporeal membrane oxygenation (ECMO)	Cost per day × mean number of days × number of patients
Complications	
ARDS	Cost per day × mean number of days of ICU stay × number of patients
Shock	Cost per day × mean number of days of ICU stay × number of patients
Acute kidney injury	Cost per day × mean number of days of ICU stay × number of patients
Rhabdomyolysis	Cost per day × mean number of days of ICU stay × number of patients
Other costs [§]	Cost per day ×mean number of days of hospital stay × number of patients

⁸Other costs include medical consumables, charge for sickbed, general care services, checkup fees, etc.

Cost of poultry slaughter (L1)
Cost of closing live-poultry markets (L ₂)
Cost of live-poultry sales(L21)
Cost of market-stall leases (L22)
Cost of live-poultry sales(L ₂₁) Cost of market-stall leases (L ₂₂)

Table 3. Driver measurement.

⊿0

(n number of days (no. of cases igated/total cases) 9 (11/25) 0	Jumber of cases	Mean number of days			Severe without death Severe with death Unknown w		vithout death Refere	
U stay eatment Antiviral			(no. of cases investigated/total cases)	Number of cases	Mean number of days (no. of cases investigated/total cases)	Number of cases	Mean number of days [¶]	Number of cases	Reference proportion of patients (%)*
eatment Antiviral	0	25	18 (19/56)	55	20 (19/39)	38	14	11	98.
Antiviral		0	12 (10/56)	55	16 (11/39)	38	6	7	76
Antibiotics	7 (3/25)	24	7 (20/56)	54	11 (11/39)	38	7	11	97
	8 (4/25)	17	11 (21/56)	40	14 (16/39)	28	9	8	71
Other drugs	9 (11/25)	25	12 (10/56)	55	16 (11/39)	38	11	11	98
Glucocorticoids	0	0	7 [§]	43	7 [§]	30	4	8	62
ntravenous immune globulin	0	0	5 [§]	37	5 [§]	26	3	7	53
Oxygen therapy Mechanical ventilation	9 (11/25)	25	18 (19/56)	56	20 (19/39)	39	9	11	100
Noninvasive	0	0	9 (7/56)	19	3 (6/39)	13	5	4	27
Invasive	0	0	8 (7/56)	41	10 (15/39)	28	4	8	58
Artificial-liver-support-system	0	0	4 [§]	11	4 [§]	7	2	2	15
rapy Continuous renal-replacement rapy	0	0	7 [§]	18	7 ^{\$}	13	4	4	26
Extracorporeal membrane genation (ECMO)	0	0	6(1/56)	12	7 (2/39)	9	3	2	18
Complications									
ARDS	0	0	12 (10/56)	50	16 (11/39)	35	6	10	71
Shock	0	0	12 (10/56)	18	16 (11/39)	13	6	4	20
Acute kidney injury	0	0	12 (10/56)	11	16 (11/39)	8	6	2	16
Rhabdomyolysis	0	0	12 (10/56)	7	16 (11/39)	5	6	1	9
her costs	9 (11/25)	25	18 (19/56)	55	20 (19/39)	38	14	11	98

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
â
0
1
8
9
10
44
11
12
13
14
15
10
16
17
18
19
2 3 4 5 6 7 8 9 10 11 21 31 4 15 16 7 18 9 20 12 22 32 4 25 26 27 8 9 30 31 32 33 4 35 36 37 8 20 10 10 10 10 10 10 10 10 10 10 10 10 10
20
21
22
23
24
27
25
26
27
28
20
29
30
31
32
33
22
34
35
36
37
20
30
39
40
41
42
43
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(number of cases) Beijing (2)	prefectures (number of cases)	Date	Live-poultry			M	1.
			sales per day (10 ⁴)	Number of days	Cost of live-poultry sales(10 ⁴ CNY)	Market-stall leases (10 ⁴ CNY)	poultry slaughter (10 ⁴ CNY)
Shanghai (32)	Beijing (2)	4.13	3.00	49	1470.00	6.93	0.50
	Shanghai (32)	4.05	11.94	57	6805.80	1703.16	20.54
Jiangsu (29)	Wuxi (4)	4.09	12.87	53	6821.10	527.40	0.40
	Yancheng (1)	4.15	8.18	47	3844.60	387.11	5.00
	Nanjing (12)	4.06	8.91	56	4989.60	567.84	8.00
	Zhenjiang (1)	4.09	8.55	53	4531.50	342.12	0.31
	Suzhou (7)	4.08	17.73	54	9574.20	265.03	0.01
	Yangzhou (1)	4.15	11.52	47	5414.40	180.17	0.20
	Xuzhou (1)	4.24	14.80	38	5624.00	380.30	0.10
	Changzhou (1)	4.11	8.94	51	4559.40	167.71	1.30
	Suqian (1)	4.02	10.14	60	6084.00	200.00	0.10
Zhejiang (45)	Huzhou (12)	4.11	6.14	51	3131.40	269.79	0.70
	Shaoxing (1)	4.22	5.31	40	2124.00	585.14	10.00
	Hangzhou (29)	4.15	12.48	47	5865.60	1200.20	24.66
	Jiaxing (2)	4.19	6.97	43	2997.10	1565.77	10.00
	Wenzhou (1)	4.21	7.02	41	2878.20	49.78	0.50
Auhui (4)	Bozhou (1)	4.09	2.89	53	1531.70	100.33	10.00
	Chuzhou (3)	3.30	6.19	63	3899.70	65.01	0.72
Fujian (5)	Longyan (1)	5.07	6.73	25	1682.50	77.40	0.82
	Fuzhou (4)	4.29	6.61	33	2181.30	287.76	100.00
Jiangxi (6)	Nanchang (5)	4.26	12.62	36	4543.20	45.72	0.10
	Yichun (1)	4.29	10.46	33	3451.80	14.09	0.08
Henan (4)	Zhoukou (1)	4.16	13.59	46	6251.40	18.28	1.60
	Kaifeng (1)	4.15	9.22	47	4333.40	14.81	1.80
	Zhengzhou (2)	4.15	9.01	47	4234.70	20.68	3.90
Hunan (2)	Shaoyang (2)	4.28	7.80	34	2652.00	70.10	100.00
Shandong (2)	Zaozhuang (2)	4.24	21.20	38	8056.00	52.36	0.66

Note: 'Date' indicates the date on which the live-poultry markets were closed; 'days' is the number of days the live-poultry markets remained closed.

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Affected	Cost of live-poultry sales	Market-stall leases (10 ⁴ CNY)	Cost of poultry slaughter (10 ⁴ CNY)	Total cost (10 ⁴ CNY)	Total cost (10 ⁴ USD)
provinces	$(10^4 \mathrm{CNY})$	(10 e1(1))	staughter (10 er(1)) (NI) US	
Beijing	14553.98	291.06	0.5	14845.54	2394.59
Shanghai	6805.8	1703.16	20.54	8529.5	1375.81
Jiangsu	124485.53	3181.5	25.62	127692.66	20596.83
Zhejiang	29982.14	2444.4	45.36	32471.9	5237.72
Anhui	113309.59	1113.01	11.52	114434.12	18458.22
Fujian	16723.29	509.04	100.82	17333.15	2795.84
Jiangxi	40832.88	255.36	0.18	41088.42	6627.56
Henan	114473.97	73.09	7.3	114554.36	18477.62
Hunan	32301.37	433.25	100	32834.62	5296.22
Shandong	180421.92	402.76	0.66	180825.34	29167.13
Guangdong	88827.4	1808.59	99.36	90735.35	14635.61
Total cost (10 ⁴	2(2212.00	10015 01	411.07	775244.04	1050/0 14
CNY)	762717.86	12215.21	411.87	775344.94	125063.14
Total cost (10 ⁴	122026 20	1070.01	((1)	1050/0 14	2204 50
USD)	123026.39	1970.31	66.43	125063.14	2394.59

Table 5. Total poultry-industry losses in the 10 affected provinces (10⁴-CNY).

Note: Date on which the live-poultry markets were closed varied among cities/counties. In Table 5, the dates when the first case of H7N9 was confirmed were adopted for estimating the total amount of poultry-industry losses in each affected province.

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Qi XP, Jiang D, Wang HL, et al. Burden of diseases in the 21st century: A case of emerging H7N9 influenza virus infection in China

Supplementary Appendix

Burden of diseases in the 21st century:

A case of emerging H7N9 influenza virus infection in China

Xiaopeng Qi^{1*}, Dong Jiang^{2*}, Hongliang Wang^{3*}, Dafang Zhuang2^{*}, Jiaqi Ma^{1*}, Jingying Fu^{2,4}, Jingdong Qu³, Yan Sun⁵, Shicheng Yu¹, Yujie Meng¹, Yaohuan Huang², Lanfang Xia¹, Yingying Li¹, Yong Wang², Guohua Wang⁵, Ke Xu⁶, Qun Zhang¹, Ming Wan¹, Xuemei Su¹, Gang Fu¹, George F Gao⁷

*These authors contributed equally to this work

- 1 National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing, China,
- 2 State Key Laboratory of Resources and Environmental Information System, Institute of Geographical Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing, China,
- 3 The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China,
- 4 University of Chinese Academy of Sciences, Beijing, China,
- 5 School of Public Health, Harbin Medical University, Harbin, China,
- 6 College of Geoscience and Surveying Engineering, China University of Mining & Technology(Beijing), Beijing, China,
- 7 Office of the Director, Chinese Center for Disease Control and Prevention, Beijing, China

Correspondence to:

Dr XP Qi, National Center for Public Health Surveillance and Information Services, Chinese Center for Disease Control and Prevention, Beijing 102206, China

qixp@chinacdc.cn

and

Prof G F Gao, Office of the Director, Chinese Center for Disease Control and Prevention, Beijing 102206, China

gaofu@chinacdc.cn

Contents

- Figure S1. The directional distribution of confirmed H7N9 cases by week
- Figure S2. Date of illness onset by case category
- Figure S3. Age distribution of each case category
- Figure S4. Poultry-industry losses of each province
- Table S1. Estimation of costs per day for confirmed H7N9 cases
- Table S2. Summary of direct medical costs
- Table S3.YLLs of confirmed H7N9 cases
- Table S4. YLDs of confirmed H7N9 cases
- Table S5. Potential poultry-industry losses of eight non-affected adjacent provinces






Figure S1. The directional distribution of confirmed H7N9 cases by week (The distribution of new confirmed H7N9 cases by week was extracted by creating two standard deviational ellipses covering 95% of the points in each ellipse to summarize the central tendency, dispersion and directional trends of confirmed H7N9 cases. The map was drawn with ArcGIS 10.0 software)




Figure S2. Date of illness onset by case category (Based on the case categories, the graph presented the number of cases within each date of onset of H7N9 cases. It was drawn with Microsoft office Excel 2010 software.)




Figure S3. Age distribution of each case category (Based on the case categories, the graph presented the number of cases within each age group of H7N9 cases. It was drawn with Microsoft office Excel 2010 software.)




Figure S4. Poultry-industry losses of each province (The map presented the total losses of poultry industry in 10 affected provinces and the proportion of each kind of losses. It was drawn with ArcGIS 10.0 software.)

Table S1. Estimation of costs	per day for confirmed H7N9 cases
-------------------------------	----------------------------------

Cost driver	Cost (CNY)	Note
Cost of examination of outpatients and		Includes tests such as live function test, kidney
inpatients in ward (laboratory and	2,500	function test, blood routine examination, routine
radiology)		urinalysis, electrocardiogram, virus detection and
Cost of examination in ICU (laboratory and radiology)	1,700 per day	isolation, chest radiology, computed tomography(CT), color Doppler ultrasound, antibody testing for hepatitis, human immunodeficiency virus and syphilis, throat swab, drug sensitive test, blood culture, ion test, blood glucose, blood sedimentation, blood gas, troponin, coagulation tests, procalcitonin (PCT), myocardial enzyme, D-dimer, C-reactive protein(CRP), B type natriuretic peptide.
Cost of treatment		
Antiviral	60 per day	Oseltamivir and peramivir, etc.
Antibiotics	350 per day	Fluoroquinolones, Piperacillin, Imipenem and Cephalosporin, etc.
	Mild: 270 per day	Reducing phlegm, relieving asthma, abating
Other drugs	Severe: 1,600 per day	fever, providing antioxidants and nutrition, inducing sedating, etc.
Glucocorticoids	70 per day	
Intravenous immune globulin	2,500 per day	
Oxygen therapy	120 per day	
ICU care	1,100 per day	
ICU monitor	500 per day	
Mechanical ventilation		
Noninvasive	400 per day	
Invasive	1,000 per day	
Artificial-liver-support-system therapy	6000 per day	
Continuous renal-replacement therapy	9000 per day	
Extracorporeal membrane oxygenation (ECMO)	10,000 per day	2
Complications		Excluding the treatments listed above
Adult respiratory distress syndro me (ARDS)	1,000 per day	Increases drug and special care services
Shock	800 per day	Increases drug, blood, fluid and hemodynamic monitoring
Acute kidney injury	300 per day	Increases drug
Rhabdomyolysis	600 per day	Increases drug use
Other costs	Mild: 200 per day	Medical consumables, charge for sickbed, general
	Severe: 800 per day	care services, checkup fee, etc.

Note: CNY=Chinese Yuan

Table S2. Summary of direct medical costs

Cost driver	Mild (n=25)	Severe without death (n=56)	Severe with death (n=39)	Unknown without death (n=11)	Total cost
Cost of examination for outpatient and inpatient	62,500	137,500	95,000	27,500	322,50
in ward (laboratory and radiology)	62,500	137,300	95,000	27,500	522,50
Cost of examination in ICU	0	1,122,000	1,033,600	71,400	2,227,00
(laboratory and radiology)	0	1,122,000	1,055,000	/1,400	2,227,00
Cost of treatment					
Antiviral	10,080	22,680	25,080	4,620	62,46
Antibiotics	47,600	154,000	137,200	25,200	364,00
Other drugs	60,750	1,056,000	972,800	113,135	2,202,68
Glucocorticoids	0	21,070	14,700	2,240	38,01
Intravenous immune globulin	0	462,500	325,000	52,500	840,00
Oxygen therapy	27,000	144,000	93,600	11,880	276,48
ICU care	0	726,000	668,800	46,200	1,441,00
ICU monitor	0	330,000	304,000	21,000	655,00
Mechanical ventilation					
Noninvasive	0	68,400	15,600	8,000	92,00
Invasive	0	328,000	280,000	32,000	640,00
Artificial-liver-support-system therapy	0	264,000	168,000	24,000	456,00
Continuous renal-replacement therapy	0	1,134,000	819,000	144,000	2,097,00
Extracorporeal membrane oxygenation (ECMO)	0	720,000	630,000	60,000	1,410,00
Complications					
ARDS	0	600,000	560,000	60,000	1,220,00
Shock	0	172,800	166,400	19,200	358,40
Acute kidney injury	0	1,056,000	1,024,000	96,000	2,176,00
Rhabdomyolysis	0	50,400	48,000	3,600	102,00
Other costs	45,000	806,400	608,000	77,000	1,536,40
Total cost (CNY)	252,930	8,359,350	7,003,180	807,075	16,422,53
Total cost (USD)*	40,469	1,337,496	1,120,509	129,132	2,627,60
Mean cost for each patient (CNY)	10,117	139,323	205,976	73,370	<u>125,363</u> 107
Mean cost for each patient (USD)*	1,619	22,292	32,956	11,739	<u>20,058 17,1</u>
Mean cost per day for each patient (CNY)	1,124	8,293	8,978	5,765	6,04
Mean cost per day for each patient (USD)*	180	1,327	1,437	922	9

*Based on average exchange rate in May,2013: 1CNY=0.16USD

2
2 3 4 5 6 7 8
6 7 8
9 10 11
12 13 14
9 10 11 12 13 14 15 16 17 18 19 20 21 22 32 4 25 26 27 28 29 30 132 33 435 36 37 82
18 19 20
21 22 23
24 25 26
27 28 29
30 31 32
33 34 35
36 37 38
39 40 41
42 43 44 45
45 46 47 48
40 49 50 51
52 53 54
54 55 56 57
58 59 60

Table S3. YLLs of confirmed H7N9 cases

	T • 6	T 10 / /	Number of	Number of		
Age group	Life expectancy at	Life expectancy at	deaths	deaths	YLL(years)*	
	age(Male)	age(Female)	(Male) (Fema		e)	
AGE<1	74.05	77.17	0	0	0.00	
AGE1-4	74.01	77.14	0	0	0.00	
AGE5-9	70.16	73.29	0	0	0.00	
AGE10-14	65.23	68.36	0	0	0.00	
AGE15-19	60.31	63.43	0	0	0.00	
AGE20-24	55.48	58.57	0	0	0.00	
AGE25-29	50.74	53.77	1	0	50.74	
AGE30-34	45.99	48.98	0	1	48.98	
AGE35-39	41.29	44.21	1	1	85.50	
AGE40-44	36.57	39.42	0	0	0.00	
AGE45-49	31.96	34.70	1	0	31.96	
AGE50-54	27.41	30.06	1	1	57.47	
AGE55-59	23.04	25.57	2	0	46.09	
AGE60-64	18.88	21.23	6	2	155.73	
AGE65-69	15.03	17.15	2	1	47.20	
AGE70-74	11.71	13.50	4	1	60.35	
AGE75-79	9.00	10.39	3	1	37.40	
AGE80-84	6.65	7.68	3	1	27.64	
AGE85-89	4.95	5.58	5	0	24.74	
AGE90-94	2.99	3.40	1	0	2.99	
AGE95-99	2.15	2.37	0	0	0.00	
AGE100+	1.53	1.67	0	0	0.00	
Total			30	9	676.78	

*YLL = years of life lost due to premature mortality.

Table S4. YLDs of confirmed H7N9 cases

	Disability weight [*]	Number of cases	Duration of disability(years)	YLD(years) [¶]
Mild	0.005	25	0.025	0.003
Severe	0.21	95	0.052	1.038
Unknown(moderate)	0.053	11	0.038	0.022
Total		131	0.115	1.064

*Disability weight: Institute for Health Metrics and Evaluation (IHME),GBD 2010 Disability Weights


[¶]YLD = years lived with disability.


2
3
4
5
5
6
7
8
õ
9
10
11
12
13
13
14
15
16
17
10
10
19
20
21
22
$\begin{bmatrix} 3 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$
23
24
25
26
20
21
28
29
30
21
31
32
33
34
25
35
36
37
38
30
40
40
41
42
43
44
 4 [
45
46
47
48
49 50 51
50
51
52
52 53
55
54
54 55
56
57
58
58


59 60

Table S5. Potential poultry-industry losses of eight non-affected adjacent provinces

Potential affected provinces	Cost of live-poultry sales(10 ⁴ CNY)	Market-stall leases (10 ⁴ CNY)	Total cost (10 ⁴ CNY)	Total cost (10 ⁴ USD)
Guangxi	126671.29	2623.68	129294.97	20687.20
Guizhou	13793.65	256.32	14049.97	2248.00
Chongqing	32341.22	2904.12	35245.34	5639.25
Hubei	76709.59	2097.12	78806.71	12609.07
Shaanxi	7859.11	213.72	8072.83	1291.65
Shanxi	9571.87	473.46	10045.33	1607.25
Hebei	78872.43	1340.10	80212.53	12834.01
Tianjin	11426.38	582.00	12008.38	1921.34
Total cost (10 ⁴ CNY)	357245.56	10490.52	367736.08	58837.77
Total cost (10 ⁴ USD)	57159.29	1678.48	58837.77	9414.04








125x90mm (300 x 300 DPI)

Page 52 of 51

BMJ Open: first published as 10.1136/bmjopen-2013-004189 on 17 January 2014. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.



117x90mm (300 x 300 DPI)